2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Open accessAbstract
AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. STRUCTURE Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the “2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” and the “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Lifestyle modification is effective for supporting moderate weight loss (5% to 10% of weight) and has favorable effects on multiple metabolic risk factors, even independent of weight loss.
“Lifestyle modification is not only effective for supporting moderate weight loss (5% to 10% of weight), but it also has favorable effects on multiple metabolic risk factors, even independent of weight loss.8–11”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline’s Secondary Prevention section (page unavailable) says structured lifestyle and risk-factor management programs facilitate weight loss in people with atrial fibrillation. It recommends a target of at least 10% weight loss, not 5%–10%, and does not establish favorable effects on multiple metabolic risk factors independent of weight loss. (LLM, conf=0.82)
Experimental — accuracy not yet measuredIntensive multicomponent behavioral weight loss interventions should include dietary changes to promote a calorie deficit of 500 to 750 kcal/day, ≥150 minutes per week of moderately vigorous aerobic activity, and ≥14 months of behavioral therapy.
“Components should include dietary changes to promote a calorie deficit of 500 to 750 kcal/day, ≥150 minutes per week of moderately vigorous aerobic activity, and ≥14 months of behavioral therapy, including self-monitoring of dietary intake, physical activity, and weight, and guided problem solving.9,10”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The Lifestyle and Risk Factor Modification section supports structured weight-loss programs, dietary interventions, and moderate-to-vigorous aerobic exercise. It specifies an exercise target of 210 minutes per week, however, and the passages found do not support the claimed 500–750 kcal/day deficit or ≥14 months of behavioral therapy. Page numbers were not available in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measuredAHA/ACC and several societies recommend intensive, multicomponent behavioral weight loss interventions led by clinicians having the ability to successfully initiate weight loss counseling.
“The AHA/ACC and several societies recommend intensive, multicomponent behavioral weight loss interventions led by clinicians having the ability to successfully initiate weight loss counseling.9–11”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline’s weight-loss recommendation in the Lifestyle and Risk Factor Modification section applies to patients with atrial fibrillation who are overweight or obese (BMI >27 kg/m²). Its supportive text says structured programs with regular progress reviews facilitate weight loss. It does not recommend intensive, multicomponent behavioral interventions led by clinicians or address clinicians’ ability to initiate weight-loss counseling; the citing sentence also omits the AF-specific population. (LLM, conf=0.87)
Experimental — accuracy not yet measuredHabitual physical activity, including activities that reduce sedentary time, aerobic physical activity, and resistance training, are associated with improvements in several CKM risk factors (HbA1c, waist circumference, fat percentage, BP) and mortality.
“In addition, habitual physical activity, including activities that reduce sedentary time, aerobic physical activity, and resistance training, are associated with improvements in several CKM risk factors (HbA1c, waist circumference, fat percentage, BP) and mortality.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline’s Lifestyle and Risk Factor Modification section recommends physical activity, particularly for sedentary people, and aerobic exercise for people with atrial fibrillation. It reports an association between regular exercise after AF develops and lower mortality. The passages do not link resistance training or reduced sedentary time to improvements in HbA1c, waist circumference, fat percentage, or BP; the mortality finding is limited to people with AF. Page numbers were not available in our copy. (LLM, conf=0.87)
Experimental — accuracy not yet measuredA heart-healthy diet and regular physical activity remain the cornerstones of therapy in patients with T2D and ASCVD, with demonstrated benefits for CKM risk profiles.
“A heart-healthy diet and regular physical activity remain the cornerstones of therapy in patients with T2D and ASCVD, with demonstrated benefits for CKM risk profiles.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline’s “Diet and Dietary Supplementation” section says a healthy diet helps prevent cardiovascular disease, and its “Physical Fitness” section recommends exercise for people with atrial fibrillation. Neither passage establishes that diet and activity are cornerstones of therapy specifically for patients with T2D and ASCVD or demonstrates benefits for their CKM risk profiles. Page numbers are not available in our copy. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Small lifestyle intervention trials suggest weight loss efficacy and safety in HFrEF.
“Small lifestyle intervention trials suggest weight loss efficacy and safety in HFrEF,8–10”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
In the Lifestyle and Risk Factor Modification section (page unavailable), the guideline reports weight loss in an intervention trial involving people with overweight or obesity and atrial fibrillation. That provides limited support for lifestyle-intervention weight loss, but the passage does not establish its efficacy or safety in patients with HFrEF. (LLM, conf=0.79)
Experimental — accuracy not yet measuredAmong patients with kidney failure receiving dialysis, CVD rates are high and the leading cause of death, with unique CVD phenotypes.
“Among patients with kidney failure (end-stage kidney disease) receiving dialysis, CVD rates are high and the leading cause of death, with unique CVD phenotypes.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The Anticoagulation in Specific Populations synopsis (page unavailable) says atrial fibrillation is highly prevalent among patients with renal failure on dialysis. That supports a high rate of one cardiovascular condition, but the cited guideline passage does not establish that CVD overall is the leading cause of death or describe unique CVD phenotypes in this population. (LLM, conf=0.78)
Experimental — accuracy not yet measuredScreening caregivers of youth populations for SDOH identifies childhood exposures to social factors that can influence CKM health across the life course.
“Screening caregivers of youth populations for SDOH identifies childhood exposures to social factors that can influence CKM health across the life course.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline’s “Addressing Health Inequities and Barriers to AF Management” section (page unavailable) discusses SDOH in patients with atrial fibrillation and cites evidence that screening and addressing SDOH can improve outcomes in other health contexts. Searches for caregivers, youth, childhood exposures, CKM health, and life-course effects found no passage addressing the claim’s specific point. Our copy is truncated, so a decisive passage may be missing. (LLM, conf=0.73)
Experimental — accuracy not yet measuredComorbid conditions such as CVD and OSA do not interfere with the success of weight loss in several studies.
“Additionally, comorbid conditions such as CVD and obstructive sleep apnea (OSA) do not interfere with the success of weight loss in several studies.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline’s ‘Weight Loss in Individuals Who Are Overweight or Obese’ section recommends weight loss to improve AF outcomes, while its ‘Sleep’ section discusses sleep-disordered breathing and AF; page numbers are unavailable in our copy. Neither section addresses whether CVD or OSA interferes with achieving weight loss. Searches for comorbidities affecting weight-loss success and for CVD or OSA as barriers found no passage establishing the claim. (LLM, conf=0.72)
Experimental — accuracy not yet measuredGLP-1-based therapies can be useful in promoting weight loss and management of comorbidities in patients who have undergone MBS and regained ≥25% of total lost weight.
“Among patients who have undergone MBS and have regained a significant amount of weight (≥25% or more of total lost weight), GLP-1–based therapies can be useful in promoting weight loss and management of comorbidities.9–13”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline’s Weight Loss section recommends weight loss for patients with atrial fibrillation who are overweight or obese and discusses bariatric surgery in relation to AF outcomes. The passages found do not address GLP-1–based therapy after metabolic and bariatric surgery (MBS) or a ≥25% weight-regain threshold (searched for GLP-1 therapy and post-bariatric weight regain). Our copy is truncated, so relevant text may be missing. (LLM, conf=0.70)
Experimental — accuracy not yet measuredRYGB and LSG comprise 90% of all MBS procedures.
“Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) comprise 90% of all procedures.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline’s lifestyle and risk-factor section discusses bariatric surgery in patients with atrial fibrillation, but does not identify RYGB or LSG or give their share of metabolic and bariatric surgery procedures. Searches for both procedure names and the 90% figure found no supporting passage in our copy; the copy is truncated. (LLM, conf=0.70)
Experimental — accuracy not yet measuredOral semaglutide appears slightly less efficacious than subcutaneous semaglutide for facilitating weight loss.
“The oral formulation appears slightly less efficacious than the subcutaneous version for facilitating weight loss.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline’s Lifestyle and Risk Factor Modification section discusses weight loss for atrial fibrillation, but not the comparative weight-loss efficacy of oral and subcutaneous semaglutide. Searches for semaglutide and the formulation comparison found no relevant passage in our copy; the copy is truncated. (LLM, conf=0.76)
Experimental — accuracy not yet measuredThis translated into a number needed to treat of 49 over 3 years to prevent 1 HF event.
“This translated into a number needed to treat of 49 over 3 years to prevent 1 HF event.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline’s Rhythm Control > Goals of Therapy With Rhythm Control section reports a reduction in a composite outcome that includes HF hospitalization, but gives no number needed to treat for an HF event. Searches for “49,” “number needed to treat,” and three-year HF prevention did not locate the claimed estimate in our copy; the copy is truncated. (LLM, conf=0.69)
Experimental — accuracy not yet measuredAlthough other measures of atherosclerosis (eg, ankle brachial index, carotid intima media thickness) have shown utility in risk assessment, studies have been limited in demonstrating their utility for guiding clinical care.
“Although other measures of atherosclerosis (eg, ankle brachial index, carotid intima media thickness) have shown utility in risk assessment,9–11 studies have been limited in demonstrating their utility for guiding clinical care.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The Anticoagulation in Specific Populations section mentions an ankle-brachial index threshold for treating peripheral artery disease, but does not assess its utility for risk assessment. Searches for carotid intima-media thickness and for evidence that these measures guide clinical care found no relevant passage in our copy; the copy may be truncated. (LLM, conf=0.70)
Experimental — accuracy not yet measuredIn the only dedicated GLP-1 RA trial of patients with diabetes and albuminuric CKD (FLOW), semaglutide demonstrated a significant reduction in HF events in the overall sample (HR, 0.74 [95% CI, 0.58-0.94]) with similar reduction in incident HF among those without baseline HF (HR, 0.68 [95% CI, 0.50-0.91]).
“In the only dedicated GLP-1 RA trial of patients with diabetes and albuminuric CKD (FLOW), semaglutide demonstrated a significant reduction in HF events in the overall sample (HR, 0.74 [95% CI, 0.58–0.94]) with similar reduction in incident HF among those without baseline HF (HR, 0.68 [95% CI, 0.50–0.91]).8,9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredNonrandomized reports across a spectrum of HF and ages do not support harm with metformin therapy.
“Nonrandomized reports across a spectrum of HF (ambulatory patients with chronic HF, a new HF diagnosis, and individuals with a recent hospitalization) and a variety of ages do not support harm with metformin therapy, though metformin is contraindicated in decompensated HF.9,30”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline passages retrieved from the Diabetes section and the Rate Control section discuss AF, diabetes, and heart-failure risks of other drugs, but not metformin. Searches for metformin and decompensated heart failure found no passage addressing metformin safety across the described HF populations; our copy is also truncated. (LLM, conf=0.72)
Experimental — accuracy not yet measuredMetformin is contraindicated in decompensated HF.
“though metformin is contraindicated in decompensated HF.9,30”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The Diabetes section discusses AF-related risks and glycemic control but does not address metformin. Searches for “metformin” and “metformin contraindicated in decompensated heart failure” found no relevant passage in our copy; the copy is truncated, so a decisive passage may be missing. (LLM, conf=0.65)
Experimental — accuracy not yet measuredInitiation of SGLT2i is efficacious in reducing risk of cardiovascular mortality, HF hospitalization, and decline in eGFR for patients with stage 4 CKM with CKD (GFR >20 mL/min/1.73 m2) and HFrEF, particularly for those with albuminuria.
“Initiation of SGLT2i is efficacious in reducing risk of the outcomes of cardiovascular mortality, HF hospitalization, and decline in eGFR for patients with stage 4 CKM with CKD (GFR >20 mL/min/1.73 m2) and HFrEF, particularly for those with albuminuria.9–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
In Rhythm Control > Antiarrhythmic Drugs for Maintenance of Sinus Rhythm (page unavailable), the guideline says SGLT2 inhibitors appear to prevent new atrial fibrillation in patients with diabetes, heart failure, or CKD. The available copy does not address the claimed reductions in cardiovascular mortality, heart-failure hospitalization, or eGFR decline at GFR >20, or a particular benefit with albuminuria (searched: SGLT2i, sodium-glucose cotransporter 2 inhibitors, albuminuria, and the specified outcomes). The copy is truncated. (LLM, conf=0.72)
Experimental — accuracy not yet measuredData on SGLT2i in patients with severely decreased kidney disease (stage G4 CKD) are more sparse, and the presence/absence of albuminuria is understudied in HF trials.
“but data are more sparse in patients with severely decreased kidney disease (stage G4 CKD), and the presence/absence of albuminuria is understudied in HF trials.9–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The Anticoagulation in Specific Populations section (page unavailable) says evidence for anticoagulation in AF patients with stage 4 CKD is largely observational. It does not address SGLT2 inhibitors or albuminuria in heart-failure trials; searches for “SGLT2i” and “albuminuria” found no relevant passage. Our copy is truncated, so the claim cannot be verified from it. (LLM, conf=0.73)
Experimental — accuracy not yet measuredSGLT2i initiation has demonstrated efficacy among patients with eGFR >20 mL/min/1.73 m2 and HFmrEF/HFpEF in reducing composite cardiovascular mortality and HF hospitalizations.
“SGLT2i initiation have demonstrated efficacy among patients with eGFR >20 mL/min/1.73 m2 and HFmrEF/HFpEF in reducing composite cardiovascular mortality and HF hospitalizations, but data are more sparse in patients with severely decreased kidney disease (stage G4 CKD), and the presence/absence of albuminuria is understudied in HF trials.9–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The available guideline passages discuss atrial fibrillation treatments and, in ‘Anticoagulation in Specific Populations’ (page unavailable), CKD in relation to anticoagulation. Searches for SGLT2 inhibitors, the eGFR >20 threshold, and HFmrEF/HFpEF outcomes found no passage addressing the claimed treatment benefit. The copy is truncated, so a missing passage cannot be ruled out. (LLM, conf=0.72)
Experimental — accuracy not yet measuredTirzepatide significantly reduced liver fat content compared with insulin degludec among persons with T2D.
“In a substudy of the randomized, open-label, parallel-group, Phase III SURPASS-3 trial, tirzepatide, a GLP-1/GIP receptor agonist approved for treatment of T2D, compared to insulin degludec, significantly reduced liver fat content among persons with T2D.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The Diabetes subsection discusses atrial fibrillation outcomes and glycemic control, but not tirzepatide or liver fat. Searches for SURPASS-3, insulin degludec, and GLP-1/GIP treatment found no passage addressing the claimed comparison. Our copy is truncated, so a relevant passage may be missing. (LLM, conf=0.70)
Experimental — accuracy not yet measuredGLP-1-based therapy can be an effective adjunctive treatment to achieve weight loss goals in MASLD, with additional favorable effects on liver histology.
“GLP-1–based therapy can be an effective adjunctive treatment to achieve weight loss goals in MASLD, with additional favorable effects on liver histology as discussed below.8,9,42”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The guideline’s “Weight Loss in Individuals Who Are Overweight or Obese” section recommends weight loss for patients with atrial fibrillation, not GLP-1–based therapy for MASLD. Searches for GLP-1 therapy, MASLD and liver histology found no passage addressing the claimed treatment effects in our copy; no page numbers are provided for these sections. (LLM, conf=0.75)
Experimental — accuracy not yet measuredMeta-analyses and cohort studies have found women with CKD are at increased risk of APOs.
“Meta-analyses and cohort studies have found that women with CKD are at increased risk of APOs.9–11,39”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
The CKD synopsis in “Anticoagulation in Specific Populations” (page unavailable) discusses stroke risk in patients with atrial fibrillation, not adverse pregnancy outcomes. Searches for CKD, pregnancy, and adverse maternal or fetal outcomes found no passage in our copy addressing the claimed risk for women with CKD; the copy is truncated. (LLM, conf=0.70)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215 · see citing works
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430 · see citing works
Self-citationApixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943 · see citing works
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300 · see citing works
Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.
Haïssaguerre, M., Jaïs, P., Shah, D. C., Takahashi, A., Hocini, M., Quiniou, G., Garrigue, S., Mouroux, A. L., Métayer, P. L., & Clémenty, J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809033391003 · Cited by 8,040 · see citing works
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,119 · see citing works
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879 · see citing works
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164 · see citing works
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051 · see citing works
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832 · see citing works
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793 · see citing works
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517 · see citing works
Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study
Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y.-H., McAnulty, J. H., Zheng, Z.-J., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005119 · Cited by 4,506 · see citing works
Self-citation(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501 · see citing works
Self-citationA comparison of rate control and rhythm control in patients with atrial fibrillation
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa021328 · Cited by 4,405 · see citing works
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279 · see citing works
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686 · see citing works
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210629 · Cited by 3,289 · see citing works
Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo
Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241201 · Cited by 3,244 · see citing works
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237 · see citing works
Hannun, A. Y., Rajpurkar, P., Haghpanahi, M., Tison, G. H., Bourn, C., Turakhia, M. P., & Ng, A. Y. (2019) · Nature Medicine · doi:10.1038/s41591-018-0268-3 · Cited by 3,148 · see citing works
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955 · see citing works
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862 · see citing works
Self-citationCalkins, H. G., Hindricks, G., Cappato, R., Kim, Y., Saad, E., Aguinaga, L., Akar, J. G., Badhwar, V., Brugada, J., Camm, A. J., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.05.012 · Cited by 2,771 · see citing works
Self-citationHindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J., Blomström-Lundqvist, C., Boriani, G., Castellá, M., Dan, G., Dilaveris, P. E., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 2,605 · see citing works
Self-citationCatheter Ablation for Atrial Fibrillation with Heart Failure
MARROUCHE, N. F., Brachmann, J., Andresen, D., Siebels, J., Boersma, L. V. A., Jordaens, L. J. L. M., Merkely, B. P., Pokushalov, E., Sanders, P., Proff, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1707855 · Cited by 2,514 · see citing works
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · see citing works
Thyroid hormone and the cardiovascular system.
Klein, I., & Ojamaa, K. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440707 · Cited by 2,300 · see citing works
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
Regitz-Zagrosek, V., Roos-Hesselink, J. W., Bauersachs, J., Blomström-Lundqvist, C., Cífková, R., De Bonis, M., Iung, B., Johnson, M. R., Kintscher, U., Kranke, P., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy340 · Cited by 2,292 · see citing works
Holmes, D. R., Reddy, V. Y., Turi, Z. G., Doshi, S. K., Sievert, H., Buchbinder, M., Mullin, C. M., & Sick, P. B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61343-x · Cited by 2,242 · see citing works
January, C. T., Wann, L. S., Calkins, H. G., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,237 · see citing works
Self-citationEarly Rhythm-Control Therapy in Patients with Atrial Fibrillation
Kirchhof, P. F., Camm, A. J., Goette, A., Brandes, A., Eckardt, L., Elvan, A., Fetsch, T., Gelder, I. C. V., Haase, D., Haegeli, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019422 · Cited by 2,227 · see citing works
Cryptogenic stroke and underlying atrial fibrillation
Sanna, T., Diener, H.-C., Passman, R. S., Di Lazzaro, V., Bernstein, R. A., Morillo, C. A., Rymer, M. M., Thijs, V., Rogers, T., Beckers, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313600 · Cited by 2,161 · see citing works
Subclinical atrial fibrillation and the risk of stroke
Healey, J. S., Connolly, S. J., Gold, M. R., Israel, C. W., Van Gelder, I. C., Capucci, A., Lau, C. P., Fain, E., Yang, S., Bailleul, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105575 · Cited by 2,100 · see citing works
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H. M., Krieger, E. V., Mack, M. J., McLeod, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.018 · Cited by 2,073 · see citing works
Physician advice for smoking cessation
Stead, L. F., Buitrago, D., Preciado, N., Sanchez, G., Hartmann-Boyce, J., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000165.pub4 · Cited by 1,955 · see citing works
(2006) · The Lancet · doi:10.1016/s0140-6736(06)68845-4 · Cited by 1,952 · see citing works
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.007 · Cited by 1,941 · see citing works
Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation
Perez, M. V., Mahaffey, K. W., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., Balasubramanian, V., Russo, A. M., Rajmane, A., Cheung, L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901183 · Cited by 1,917 · see citing works
Self-citation2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896 · see citing works
Self-citationHolmes, D. R., Kar, S., Price, M. J., Whisenant, B. K., Sievert, H., Doshi, S. K., Huber, K., & Reddy, V. Y. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.029 · Cited by 1,850 · see citing works
Sweeney, M. O., Hellkamp, A. S., Ellenbogen, K. A., Greenspon, A. J., Freedman, R. A., Lee, K. L., & Lamas, G. A. (2003) · Circulation · doi:10.1161/01.cir.0000072769.17295.b1 · Cited by 1,773 · see citing works
Schnabel, R. B., Yin, X., Gona, P., Larson, M. G., Beiser, A. S., McManus, D. D., Newton-Cheh, C., Lubitz, S. A., Magnani, J. W., Ellinor, P. T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61774-8 · Cited by 1,746 · see citing works
Self-citationDewilde, W. J., Oirbans, T., Verheugt, F. W., Kelder, J. C., De Smet, B. J., Herrman, J.-P., Adriaenssens, T., Vrolix, M., Heestermans, A. A., Vis, M. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62177-1 · Cited by 1,719 · see citing works
Stroke Prevention in Atrial Fibrillation Study. Final results.
Prevention, S., & Atrial Fibrillation Investigators (1991) · Circulation · doi:10.1161/01.cir.84.2.527 · Cited by 1,696 · see citing works
Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation
Blackshear, J. L., & Odell, J. A. (1996) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00887-x · Cited by 1,686 · see citing works
Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E. A., Bhatt, D. L., Birtcher, K. K., Blankstein, R., Boyd, J. H., Bullock-Palmer, R. P., Conejo, T., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001029 · Cited by 1,684 · see citing works
Self-citation2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Lawton, J. S., Tamis‐Holland, J. E., Bangalore, S., Bates, E., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.006 · Cited by 1,651 · see citing works
Self-citationStout, K. K., Daniels, C. J., Aboulhosn, J. A., Bozkurt, B., Broberg, C. S., Colman, J. M., Crumb, S. R., Dearani, J. A., Fuller, S., Gurvitz, M., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000603 · Cited by 1,602 · see citing works
Self-citationPrevention of bleeding in patients with atrial fibrillation undergoing PCI
Gibson, C. M., Mehran, R., Bode, C., Halperin, J., Verheugt, F. W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611594 · Cited by 1,590 · see citing works
Rhythm control versus rate control for atrial fibrillation and heart failure
Roy, D., Talajic, M., Nattel, S., Wyse, D. G., Dorian, P., Lee, K. L., Bourassa, M. G., Arnold, J. M. O., Buxton, A. E., Camm, A. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708789 · Cited by 1,585 · see citing works
Packer, D. L., Mark, D. B., Robb, R. A., Monahan, K. H., Bahnson, T. D., Poole, J. E., Noseworthy, P. A., Rosenberg, Y., Jeffries, N. O., Mitchell, L. B., et al. (2019) · JAMA · doi:10.1001/jama.2019.0693 · Cited by 1,538 · see citing works
Self-citationEpidemiologic assessment of chronic atrial fibrillation and risk of stroke: The fiamingham Study
Wolf, P. A., Dawber, T. R., Thomas, H. E., & Kannel, W. B. (1978) · Neurology · doi:10.1212/wnl.28.10.973 · Cited by 1,526 · see citing works
Dabigatran versus warfarin in patients with mechanical heart valves
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300615 · Cited by 1,506 · see citing works
Kück, K., Cappato, R., Siebels, J., & Rüppel, R. (2000) · Circulation · doi:10.1161/01.cir.102.7.748 · Cited by 1,474 · see citing works
Marrouche, N. F., Wilber, D., Hindricks, G., Jais, P., Akoum, N., Marchlinski, F., Kholmovski, E., Burgon, N., Hu, N., Mont, L., et al. (2014) · JAMA · doi:10.1001/jama.2014.3 · Cited by 1,473 · see citing works
The surgical treatment of atrial fibrillation
Cox, J. L., Schuessler, R. B., D’Agostino, H. J., Stone, C. M., Chang, B.-C., Cain, M. E., Corr, P. B., & Boineau, J. P. (1991) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)36684-x · Cited by 1,464 · see citing works
Electrical, contractile and structural remodeling during atrial fibrillation
Allessie, M. A. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00258-4 · Cited by 1,455 · see citing works
Obesity and the risk of new-onset atrial fibrillation
Wang, T. J. (2004) · JAMA · doi:10.1001/jama.292.20.2471 · Cited by 1,427 · see citing works
Jackman, W. M., Wang, X., Friday, K. J., Roman, C. A., Moulton, K. P., Beckman, K. J., McClelland, J. H., Twidale, N., Hazlitt, H. A., Prior, M. I., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106063242301 · Cited by 1,422 · see citing works
Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation
Cannon, C. P., Bhatt, D. L., Oldgren, J., Lip, G. Y. H., Ellis, S. G., Kimura, T., Maeng, M., Merkely, B., Zeymer, U., Gropper, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708454 · Cited by 1,383 · see citing works
C-Reactive Protein Elevation in Patients With Atrial Arrhythmias
Chung, M. K., Martin, D. O., Sprecher, D. L., Wazni, O. M., KANDERIAN, A. S., Carnes, C. A., Bauer, J. A., TCHOU, P. J., Niebauer, M. J., Natale, A., et al. (2001) · Circulation · doi:10.1161/hc4901.101760 · Cited by 1,375 · see citing works
Self-citationReversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C. M., Buller, H. R., & Levi, M. M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,353 · see citing works
Klein, I., & Danzi, S. (2007) · Circulation · doi:10.1161/circulationaha.106.678326 · Cited by 1,324 · see citing works
Colilla, S., Crow, A., Petkun, W., Singer, D. E., Simon, T. A., & Liu, X. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.05.063 · Cited by 1,323 · see citing works
US Health Care Spending by Payer and Health Condition, 1996-2016
Dieleman, J. L., Cao, J., Chapin, A., Chen, C., Li, Z., Liu, A., Horst, C., Kaldjian, A., Matyasz, T., Scott, K. W., et al. (2020) · JAMA · doi:10.1001/jama.2020.0734 · Cited by 1,313 · see citing works
Brugada, J., Katritsis, D. G., Arbelo, E., Arribas, F., Bax, J. J., Blomström‐Lundqvist, C., Calkins, H. G., Corrado, D., Deftereos, S. G., Diller, G., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz467 · Cited by 1,278 · see citing works
Self-citationAtrial fibrillation in patients with cryptogenic stroke
Gladstone, D. J., Spring, M., Dorian, P., Panzov, V., Thorpe, K. E., Hall, J., Vaid, H., O'Donnell, M., Laupacis, A., Côté, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311376 · Cited by 1,276 · see citing works
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal
Schotten, U., Verheule, S., Kirchhof, P., & Goette, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00031.2009 · Cited by 1,273 · see citing works
A multicenter risk index for atrial fibrillation after cardiac surgery
Mathew, J. P. (2004) · JAMA · doi:10.1001/jama.291.14.1720 · Cited by 1,234 · see citing works
Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation
Lopes, R. D., Heizer, G., Aronson, R., Vora, A. N., Massaro, T., Mehran, R., Goodman, S. G., Windecker, S., Darius, H., Li, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817083 · Cited by 1,228 · see citing works
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
Douketis, J. D., Spyropoulos, A. C., Kaatz, S., Becker, R. C., Caprini, J. A., Dunn, A. S., Garcia, D. A., Jacobson, A., Jaffer, A. K., Kong, D. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501035 · Cited by 1,184 · see citing works
Wilber, D. J., Pappone, C., Neuzil, P., De Paola, A., Marchlinski, F., Natale, A., Macle, L., Daoud, E. G., Calkins, H., Hall, B., et al. (2010) · JAMA · doi:10.1001/jama.2009.2029 · Cited by 1,170 · see citing works
Criteria for Evaluation of Novel Markers of Cardiovascular Risk
Hlatky, M., Greenland, P., Arnett, D., Ballantyne, C., Criqui, M., Elkind, M., Go, A., Harrell, F. E. J., Hong, Y.-L., Howard, B., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192278 · Cited by 1,153 · see citing works
Self-citationIdarucizumab for Dabigatran Reversal — Full Cohort Analysis
Pollack, C. V., Reilly, P. A., van Ryn, J., Eikelboom, J. W., Glund, S., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kam, C. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707278 · Cited by 1,148 · see citing works
Amiodarone to Prevent Recurrence of Atrial Fibrillation
Roy, D., Talajic, M. R., Dorian, P., Connolly, S. J., Eisenberg, M. J., Green, M. S., Kuś, T., Lambert, J., Dubuc, M., Gagné, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421302 · Cited by 1,142 · see citing works
Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
Hohnloser, S. H., Crijns, H. J. G. M., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C. T., & Connolly, S. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803778 · Cited by 1,125 · see citing works
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,124 · see citing works
Wazni, O. M., Marrouche, N. F., Martin, D. O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Schweikert, R., Brachmann, J., Gunther, J., et al. (2005) · JAMA · doi:10.1001/jama.293.21.2634 · Cited by 1,121 · see citing works
2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease
Stout, K., Daniels, C. J., Aboulhosn, J., Bozkurt, B., Broberg, C. S., Colman, J. M., Crumb, S. R., Dearani, J. A., Fuller, S., Gurvitz, M. Z., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.1029 · Cited by 1,115 · see citing works
Self-citationEchocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study.
Vaziri, S. M., Larson, M. G., Benjamin, E. J., & Levy, D. (1994) · Circulation · doi:10.1161/01.cir.89.2.724 · Cited by 1,073 · see citing works
Self-citationThromboembolic and bleeding complications in patients with mechanical heart valve prostheses.
Cannegieter, S. C., Rosendaal, F. R., & Briët, E. (1994) · Circulation · doi:10.1161/01.cir.89.2.635 · Cited by 1,072 · see citing works
5-Year Outcomes After Left Atrial Appendage Closure
Reddy, V. Y., Doshi, S. K., Kar, S., Gibson, D. N., Price, M. J., Huber, K., Horton, R., Buchbinder, M., Neužil, P., Gordon, N. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.021 · Cited by 1,039 · see citing works
Schnabel, R. B., SULLIVAN, L. M., Levy, D. A., Pencina, M. J., Massaro, J. M., D’Agostino, R. B., Newton‐Cheh, C., Yamamoto, J. F., Magnani, J. W., Tadros, T. M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60443-8 · Cited by 1,038 · see citing works
Self-citationLong-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort
Pathak, R. K., Middeldorp, M. E., Meredith, M., Mehta, A. B., Mahajan, R., Wong, C. X., Twomey, D., Elliott, A. D., Kalman, J. M., Abhayaratna, W. P., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.002 · Cited by 1,036 · see citing works
Self-citationLenient versus strict rate control in patients with atrial fibrillation
Van Gelder, I. C., Groenveld, H. F., Crijns, H. J. G. M., Tuininga, Y. S., Tijssen, J. G. P., Alings, A. M., Hillege, H. L., Bergsma-Kadijk, J. A., Cornel, J. H., Kamp, O., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001337 · Cited by 1,033 · see citing works
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
Hart, R. G., Sharma, M., Mundl, H., Kasner, S. E., Bangdiwala, S. I., Berkowitz, S. D., Swaminathan, B., Lavados, P. M., Wang, Y., Wang, Y., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802686 · Cited by 1,032 · see citing works
Reddy, V. Y., Sievert, H., Halperin, J., Doshi, S. K., Buchbinder, M., Neuzil, P., Huber, K., Whisenant, B., Kar, S., Swarup, V., et al. (2014) · JAMA · doi:10.1001/jama.2014.15192 · Cited by 1,018 · see citing works
Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial Infarction
The Cardiac Arrhythmia Suppression Trial II Investigators* (1992) · New England Journal of Medicine · doi:10.1056/nejm199207233270403 · Cited by 1,012 · see citing works
Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction
Torp-Pedersen, C. T., Møller, M., Bloch-Thomsen, P.-E., Køber, L., Sandøe, E., Egstrup, K., Agner, E., Carlsen, J. E., Videbæk, J., Marchant, B., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411201 · Cited by 1,012 · see citing works
Gage, B. F., Yan, Y., Milligan, P. E., Waterman, A. D., Culverhouse, R., Rich, M. W., & Radford, M. J. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.017 · Cited by 1,008 · see citing works
Ommen, S. R., Mital, S. R., Burke, M. A., Day, S. M., Deswal, A. M., Elliot, P. M., Evanovich, L. L., Hung, J., Joglar, J. A., Kantor, P. F., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.044 · Cited by 997 · see citing works
Self-citationKCNQ1 Gain-of-Function Mutation in Familial Atrial Fibrillation
Chen, Y.-H., Xu, S.-J., Bendahhou, S., Wang, X.-L., Wang, Y., Xu, W.-Y., Jin, H., Sun, H., Su, X.-Y., Zhuang, Q.-N., et al. (2003) · Science · doi:10.1126/science.1077771 · Cited by 989 · see citing works
Ventricular Pacing or Dual-Chamber Pacing for Sinus-Node Dysfunction
Lamas, G. A., Lee, K. L., Sweeney, M. O., Silverman, R., León, A. R., Yee, R. K., Marinchak, R. A., Flaker, G., SCHRON, E. B., Orav, E. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013040 · Cited by 988 · see citing works
Circumferential Pulmonary-Vein Ablation for Chronic Atrial Fibrillation
Oral, H., Pappone, C., Chugh, A., Good, E. D., Bogun, F. M., Pelosi, F., Bates, E., Lehmann, M. H., Vicedomini, G., Augello, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa050955 · Cited by 975 · see citing works
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Crowther, M. A., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Lawrence, J. H., Yue, P., Bronson, M. D., Lu, G., Conley, P. B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814051 · Cited by 970 · see citing works
Increased Mortality after Dronedarone Therapy for Severe Heart Failure
Køber, L., Torp-Pedersen, C. T., McMurray, J. J. V., Gøtzsche, O., Lévy, S., Crijns, H. J. G. M., Amlie, J., & Carlsen, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800456 · Cited by 969 · see citing works
Linde, C. M., Leclercq, C., Rex, S., Garrigue, S., Lavergne, T., Cazeau, S., McKenna, W. J., Fitzgerald, M., Deharo, J., Alonso, C., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01932-0 · Cited by 965 · see citing works
Use of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation
Klein, A. L., Grimm, R. A., Murray, R. D., Apperson-Hansen, C., ASINGER, R. W., Black, I. W., Davidoff, R., Erbel, R., Halperin, J. L., Orsinelli, D. A., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441901 · Cited by 952 · see citing works
Pathak, R. K., Middeldorp, M. E., Lau, D. H., Mehta, A. B., Mahajan, R., Twomey, D., Alasady, M., Hanley, L., Antic, N. A., McEvoy, R. D., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.028 · Cited by 949 · see citing works
Self-citationCryoballoon Ablation of Pulmonary Veins for Paroxysmal Atrial Fibrillation
Packer, D. L., Kowal, R. C., Wheelan, K. R., Irwin, J. M., Champagne, J., Guerra, P. G., Dubuc, M., Reddy, V. Y., Nelson, L., Holcomb, R. G., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.064 · Cited by 899 · see citing works
Catheter Ablation for Atrial Fibrillation in Congestive Heart Failure
Hsu, L., Jaı̈s, P., Sanders, P., Garrigue, S., Hocini, M., Sacher, F., Takahashi, Y., Rotter, M., Pasquié, J., Scavée, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041018 · Cited by 890 · see citing works
Self-citationCatheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation
Jaı̈s, P., CAUCHEMEZ, B., Macle, L., Daoud, E. G., Khairy, P., Subbiah, R. N., Hocini, M., Extramiana, F., Sacher, F., Bordachar, P., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.772582 · Cited by 889 · see citing works
Odutayo, A., Wong, C. X. J., Hsiao, A. J., Hopewell, S., Altman, D. G., & Emdin, C. A. (2016) · BMJ · doi:10.1136/bmj.i4482 · Cited by 888 · see citing works
Alonso, Á., Krijthe, B. P., Aspelund, T., Stepas, K. A., Pencina, M. J., Moser, C., Sinner, M. F., Sotoodehnia, N., Fontes, J. D., Janssens, A. C. J. W., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.000102 · Cited by 886 · see citing works
Self-citationBiase, L. D., Mohanty, P. K., Mohanty, S., Santangeli, P., Trivedi, C. G., Lakkireddy, D., Reddy, M., Jaı̈s, P., Themistoclakis, S., Russo, A. D., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.019406 · Cited by 880 · see citing works
Self-citationBiobank-driven genomic discovery yields new insight into atrial fibrillation biology
Nielsen, J. B., Thorolfsdottir, R. B., Fritsche, L. G., Zhou, W., Skov, M. W., Graham, S. E., Herron, T. J., McCarthy, S., Schmidt, E. M., Sveinbjornsson, G., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0171-3 · Cited by 876 · see citing works
Atrial Fibrillation Begets Heart Failure and Vice Versa
Santhanakrishnan, R., Wang, N., Larson, M. G., Magnani, J. W., McManus, D. D., Lubitz, S. A., Ellinor, P. T., Cheng, S. C., Vasan, R. S., Lee, D. S., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.018614 · Cited by 874 · see citing works
Self-citationA New Risk Scheme to Predict Warfarin-Associated Hemorrhage
Fang, M. C., Go, A. S., Chang, Y., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N. V., & Singer, D. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.03.031 · Cited by 853 · see citing works
Atrial Fibrillation Pathophysiology
Iwasaki, Y., Nishida, K., Kato, T., & Nattel, S. (2011) · Circulation · doi:10.1161/circulationaha.111.019893 · Cited by 852 · see citing works
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain
Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E. A., Bhatt, D. L., Birtcher, K. K., Blankstein, R., Boyd, J. H., Bullock-Palmer, R. P., Conejo, T., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.053 · Cited by 849 · see citing works
Self-citationCalkins, H., Reynolds, M. R., Spector, P., Sondhi, M., Xu, Y., Martin, A., Williams, C. J., & Sledge, I. (2009) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.108.824789 · Cited by 847 · see citing works
Andersen, H. R., Nielsen, J. C., Thomsen, P. E. B., Thuesen, L., Mortensen, P. T., Vesterlund, T., & Pedersen, A. K. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03425-9 · Cited by 841 · see citing works
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation
Andrade, J. G., Wells, G. A., Deyell, M. W., Bennett, M. T., Essebag, V., Champagne, J., Roux, J.-F., Yung, D., Skanes, A. C., Khaykin, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2029980 · Cited by 841 · see citing works
Self-citationVentricular fibrillation in the Wolff-Parkinson-White syndrome
Klein, G. J., Bashore, T. M., Sellers, T. D., Pritchett, E. L. C., Smith, W. M., & Gallagher, J. J. (1979) · New England Journal of Medicine · doi:10.1056/nejm197911153012003 · Cited by 830 · see citing works
Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826 · see citing works
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
Diener, H., Sacco, R. L., Easton, J. D., Granger, C. B., Bernstein, R. A., Uchiyama, S., Kreuzer, J., Cronin, L., Cotton, D., Grauer, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813959 · Cited by 826 · see citing works
The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction
The Multicenter Diltiazem Postinfarction Trial Research Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190701 · Cited by 823 · see citing works
Healey, J. S., Baranchuk, A., Crystal, E., Morillo, C. A., Garfinkle, M., Yusuf, S., & Connolly, S. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.11.070 · Cited by 822 · see citing works
Sarode, R., Milling, T. J., Refaai, M. A., Mangione, A., Schneider, A., Durn, B. L., & Goldstein, J. N. (2013) · Circulation · doi:10.1161/circulationaha.113.002283 · Cited by 812 · see citing works
Ganesan, A. N., Shipp, N. J., Brooks, A. G., Kuklik, P., Lau, D. H., Lim, H. S., Sullivan, T., Roberts‐Thomson, K. C., & Sanders, P. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.004549 · Cited by 800 · see citing works
Self-citationRole of the Autonomic Nervous System in Atrial Fibrillation
Chen, P., Chen, L. S., Fishbein, M. C., Lin, S., & Nattel, S. (2014) · Circulation Research · doi:10.1161/circresaha.114.303772 · Cited by 798 · see citing works
Self-citationGoette, A., Kalman, J. M., Aguinaga, L., Akar, J. G., Cabrera, J. Á., Chen, S. A., Chugh, S. S., Corradi, D., d’Ávila, A., Dobrev, D., et al. (2016) · Heart Rhythm · doi:10.1016/j.hrthm.2016.05.028 · Cited by 785 · see citing works
Self-citationAbed, H. S., Wittert, G. A., Leong, D. P., Shirazi, M. G., Bahrami, B., Middeldorp, M. E., Lorimer, M. F., Lau, D. H., Antic, N. A., Brooks, A. G., et al. (2013) · JAMA · doi:10.1001/jama.2013.280521 · Cited by 776 · see citing works
Self-citationAssociation of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure
Rathore, S. S., Curtis, J. P., Wang, Y., Bristow, M. R., & Krumholz, H. M. (2003) · JAMA · doi:10.1001/jama.289.7.871 · Cited by 772 · see citing works
Multi-ethnic genome-wide association study for atrial fibrillation
Roselli, C., Chaffin, M. D., Weng, L.-C. C., Aeschbacher, S., Ahlberg, G., Albert, C. M., Almgren, P., Alonso, Á., Anderson, C. D., Aragam, K. G., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0133-9 · Cited by 754 · see citing works
Self-citationGlotzer, T. V., Hellkamp, A. S., Zimmerman, J., Sweeney, M. O., Yee, R., Marinchak, R., Cook, J., Paraschos, A., Love, J., Radoslovich, G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000057981.70380.45 · Cited by 750 · see citing works
Amiodarone versus sotalol for atrial fibrillation
Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041705 · Cited by 749 · see citing works
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke
Whitlock, R. P., Belley‐Côté, E. P., Paparella, D., Healey, J. S., Brady, K., Sharma, M., Reents, W., Budera, P., Baddour, A. J., Fila, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101897 · Cited by 741 · see citing works
Thyroid hormones and cardiovascular disease
Jabbar, A., Pingitore, A., Pearce, S. H. S., Zaman, A., Iervasi, G., & Razvi, S. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.174 · Cited by 729 · see citing works
Reddy, V. Y., Möbius-Winkler, S., Miller, M. A., Neuzil, P., Schuler, G., Wiebe, J., Sick, P., & Sievert, H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.035 · Cited by 727 · see citing works
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation
Cosedis Nielsen, J., Johannessen, A., Raatikainen, P., Hindricks, G., Walfridsson, H., Kongstad, O., Pehrson, S., Englund, A., Hartikainen, J., Mortensen, L. S., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113566 · Cited by 720 · see citing works
Stangier, J., Rathgen, K., Stähle, H., & Mazur, D. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318170-000000000-00000 · Cited by 720 · see citing works
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Ommen, S. R., Mital, S. R., Burke, M. A., Day, S. M., Deswal, A. M., Elliot, P. M., Evanovich, L. L., Hung, J., Joglar, J. A., Kantor, P. F., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.045 · Cited by 716 · see citing works
Self-citationKhairy, P., Van Hare, G. F., Balaji, S., Berul, C. I., Cecchin, F., Cohen, M. I., Daniels, C. J., Deal, B. J., Dearani, J. A., Groot, N. D., et al. (2014) · Heart Rhythm · doi:10.1016/j.hrthm.2014.05.009 · Cited by 709 · see citing works
Vranckx, P., Valgimigli, M., Eckardt, L., Tijssen, J. G. P., Lewalter, T., Gargiulo, G., Batushkin, V., Campo, G. C., Lysak, Z., Ip, V., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31872-0 · Cited by 698 · see citing works
Huxley, R. R., Lopez, F. L., Folsom, A. R., Agarwal, S. K., Loehr, L. R., Soliman, E. Z., Maclehose, R., Konety, S., & Alonso, A. (2011) · Circulation · doi:10.1161/circulationaha.110.009035 · Cited by 697 · see citing works
Sposato, L. A., Cipriano, L. E., Saposnik, G., Vargas, E. R., Riccio, P. M., & Hachinski, V. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70027-x · Cited by 694 · see citing works
Pappone, C., Augello, G., Sala, S., Gugliotta, F., Vicedomini, G., Gulletta, S., Paglino, G., Mazzone, P., Sora, N., Greiss, I., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.037 · Cited by 685 · see citing works
Temporal relationship between subclinical atrial fibrillation and embolic events
Brambatti, M., Connolly, S. J., Gold, M. R., Morillo, C. A., Capucci, A., Muto, C., Lau, C. P., Van Gelder, I. C., Hohnloser, S. H., Carlson, M., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.007825 · Cited by 676 · see citing works
Morillo, C. A., Verma, A., Connolly, S. J., Kuck, K. H., Nair, G. M., Champagne, J., Sterns, L. D., Beresh, H., Healey, J. S., Natale, A., et al. (2014) · JAMA · doi:10.1001/jama.2014.467 · Cited by 667 · see citing works
Electrical reversion of cardiac arrhythmias.
Lown, B. (1967) · Heart · doi:10.1136/hrt.29.4.469 · Cited by 664 · see citing works
Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation
Yao, C., Veleva, T., Scott, L., Cao, S., Li, L., Chen, G., Jeyabal, P., Pan, X., Alsina, K. M., Abu-Taha, I., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035202 · Cited by 661 · see citing works
Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction
Prabhu, S., Taylor, A. J., Costello, B. T., Kaye, D. M., McLellan, A. J. A., Voskoboinik, A., Sugumar, H., Lockwood, S. M., Stokes, M. B., Pathik, B., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.041 · Cited by 661 · see citing works
Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation
Wazni, O. M., Dandamudi, G., Sood, N. A., HOYT, R. H., Tyler, J. D., Durrani, S., Niebauer, M. J., Makati, K. J., Halperin, B. D., Gauri, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2029554 · Cited by 656 · see citing works
Osmancik, P. P., Heřman, D., Neužil, P., Hála, P., Táborský, M., Kala, P., Poloczek, M., Šťásek, J., Haman, L., Branny, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.067 · Cited by 654 · see citing works
Tsang, T. S. M., Gersh, B. J., Appleton, C. P., Tajik, A. J., Barnes, M. E., Bailey, K. R., Oh, J. K., Leibson, C. L., Montgomery, S. C., & Seward, J. B. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02373-2 · Cited by 652 · see citing works
Biase, L. D., Burkhardt, J. D., Mohanty, P. K., Sánchez, J., Mohanty, S., Horton, R., Gallinghouse, G. J., BAILEY, S. M., ZAGRODZKY, J. D., Santangeli, P., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.928903 · Cited by 648 · see citing works
Self-citationWarfarin, hematoma expansion, and outcome of intracerebral hemorrhage
Flibotte, J. J., Hagan, N., O’Donnell, J. S., Greenberg, S. M., & Rosand, J. M. (2004) · Neurology · doi:10.1212/01.wnl.0000138428.40673.83 · Cited by 632 · see citing works
Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter
Singh, B. N., Connolly, S. J., Crijns, H. J. G. M., Roy, D., Kowey, P. R., Capucci, A., Radzik, D., Aliot, E., & Hohnloser, S. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054686 · Cited by 632 · see citing works
Voigt, N., Li, N., Wang, Q., Wang, W., Trafford, A. W., Abu-Taha, I., Sun, Q., Wieland, T., Ravens, U., Nattel, S., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.067306 · Cited by 630 · see citing works
Mark, D. B., Anstrom, K. J., Sheng, S., Piccini, J. P., Baloch, K. N., Monahan, K. H., Daniels, M. R., Bahnson, T. D., Poole, J. E., Rosenberg, Y., et al. (2019) · JAMA · doi:10.1001/jama.2019.0692 · Cited by 629 · see citing works
Self-citationDronedarone in High-Risk Permanent Atrial Fibrillation
Connolly, S. J., Camm, A. J., Halperin, J. L., Joyner, C., Alings, M., Amerena, J., Atar, D., Avezum, Á., Blomström, P., Borggrefe, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109867 · Cited by 628 · see citing works
Patti, G., Chello, M., Candura, D., Pasceri, V., D’Ambrosio, A., Covino, E., & Sciascio, G. D. (2006) · Circulation · doi:10.1161/circulationaha.106.621763 · Cited by 617 · see citing works
Atrial L-type Ca2+ currents and human atrial fibrillation.
Wagoner, D. V. V., Pond, A. L., Lamorgese, M., Rossie, S., McCarthy, P., & Nerbonne, J. (1999) · Circulation Research · doi:10.1161/01.res.85.5.428 · Cited by 617 · see citing works
Self-citationDuration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT
Gelder, I. C. V., Healey, J. S., Crijns, H. J. G. M., Wang, J., Hohnloser, S. H., Gold, M. R., Capucci, A., Lau, C., Morillo, C. A., Hobbelt, A. H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx042 · Cited by 604 · see citing works
Udo, E. O., Zuithoff, N. P. A., van Hemel, N. M., de Cock, C. C., Hendriks, T., Doevendans, P. A., & Moons, K. G. M. (2012) · Heart Rhythm · doi:10.1016/j.hrthm.2011.12.014 · Cited by 597 · see citing works
Left Ventricular‐Based Cardiac Stimulation Post AV Nodal Ablation Evaluation (The PAVE Study)
Doshi, R. N., Daoud, E. G., Fellows, C. L., TURK, K. T., Duran, A., Hamdan, M. H., Pires, L. A., & for the PAVE Study Group (2005) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2005.50062.x · Cited by 596 · see citing works
Page, R. L., Joglar, J. A., Caldwell, M. A., Calkins, H., Conti, J. B., Deal, B. J., Estes, N. A. M., Field, M. E., Goldberger, Z. D., Hammill, S. C., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000311 · Cited by 595 · see citing works
Self-citationDetermination of Therapeutic and Toxic Serum Digoxin Concentrations by Radioimmunoassay
Smith, T. W., Butler, V. P., & Haber, E. (1969) · New England Journal of Medicine · doi:10.1056/nejm196911272812203 · Cited by 584 · see citing works
Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation
Birnie, D. H., Healey, J. S., Wells, G. A., Verma, A., TANG, A. S. L., Krahn, A. D., Simpson, C. S., Paredes, F. A., Coutu, B., Leiria, T. L. L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302946 · Cited by 583 · see citing works
Self-citationDeshmukh, A. J., Patel, N., Pant, S., Shah, N. N., Chothani, A., Mehta, K. D., Grover, P. M., Singh, V., Vallurupalli, S., Savani, G. T., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.003862 · Cited by 580 · see citing works
Self-citationOlsson, L. G., Swedberg, K., Ducharme, A., Granger, C. B., Michelson, E. L., McMurray, J. J. V., Puu, M., Yusuf, S., & Pfeffer, M. A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.01.060 · Cited by 574 · see citing works
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
Yasuda, S., Kaikita, K., Akao, M., Ako, J., Matoba, T., Nakamura, M., Miyauchi, K., Hagiwara, N., Kimura, K., Hirayama, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904143 · Cited by 574 · see citing works
Calcium Signaling and Cardiac Arrhythmias
Landstrom, A. P., Dobrev, D., & Wehrens, X. H. T. (2017) · Circulation Research · doi:10.1161/circresaha.117.310083 · Cited by 574 · see citing works
Kuramatsu, J. B., Gerner, S. T., Schellinger, P. D., Glahn, J., Endres, M., Sobesky, J., Flechsenhar, J., Neugebauer, H., Jüttler, E., Grau, A., et al. (2015) · JAMA · doi:10.1001/jama.2015.0846 · Cited by 568 · see citing works
Andrade, J. G., Aguilar, M., Atzema, C. L., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 568 · see citing works
Self-citationPassive Detection of Atrial Fibrillation Using a Commercially Available Smartwatch
Tison, G. H., Sanchez, J. M., Ballinger, B., Singh, A., Olgin, J. E., Pletcher, M. J., Vittinghoff, E., Lee, E. S., Fan, S. M., Gladstone, R. A., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0136 · Cited by 566 · see citing works
Self-citationPiccini, J. P., Hammill, B. G., Sinner, M. F., Jensen, P. N., Hernandez, A. F., Heckbert, S. R., Benjamin, E. J., & Curtis, L. H. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.962688 · Cited by 565 · see citing works
Self-citationOutward K + Current Densities and Kv1.5 Expression Are Reduced in Chronic Human Atrial Fibrillation
Wagoner, D. R. V., Pond, A. L., McCarthy, P. M., Trimmer, J. S., & Nerbonne, J. M. (1997) · Circulation Research · doi:10.1161/01.res.80.6.772 · Cited by 556 · see citing works
Self-citationIdentification of a Genetic Locus for Familial Atrial Fibrillation
Brugada, R., Tapscott, T., Czernuszewicz, G. Z., Marian, A. J., Iglesias, A., Mont, L., Brugada, J., Girona, J. M., Domingo, A., Bachinski, L. L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703273361302 · Cited by 554 · see citing works
López-López, J. A., Sterne, J. A. C., Thom, H. H. Z., Higgins, J. P. T., Hingorani, A. D., Okoli, G. N., Davies, P. A., Bodalia, P. N., Bryden, P. A., Welton, N. J., et al. (2017) · BMJ · doi:10.1136/bmj.j5058 · Cited by 552 · see citing works
Chung, M. K., Eckhardt, L. L., Chen, L. Y., Ahmed, H. M., Gopinathannair, R., Joglar, J. A., Noseworthy, P. A., Pack, Q. R., Sanders, P., & Trulock, K. M. (2020) · Circulation · doi:10.1161/cir.0000000000000748 · Cited by 549 · see citing works
Self-citationViles-González, J. F., Kar, S., Douglas, P. S., Dukkipati, S. R., Feldman, T. E., Horton, R., Holmes, D. R., & Reddy, V. Y. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.028 · Cited by 545 · see citing works
Pathak, R. K., Elliott, A., Middeldorp, M. E., Meredith, M., Mehta, A. B., Mahajan, R., Hendriks, J. M. L., Twomey, D., Kalman, J. M., Abhayaratna, W. P., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.488 · Cited by 544 · see citing works
Self-citationChronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation
Alonso, Á., Norby, F. L., Matsushita, K., Loehr, L. R., Agarwal, S. K., Chen, L. Y., Soliman, E. Z., Astor, B. C., & Coresh, J. (2011) · Circulation · doi:10.1161/circulationaha.111.020982 · Cited by 544 · see citing works
Self-citationPerioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant
Douketis, J. D., Spyropoulos, A. C., Duncan, J. M., Carrier, M., Gal, G. L., Tafur, A. J., Vanassche, T., Verhamme, P. B., Shivakumar, S., Gross, P. L., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2431 · Cited by 538 · see citing works
Manning, W. J., Silverman, D. I., Katz, S. E., Riley, M. F., Come, P. C., Doherty, R. M., Munson, J. T., & Douglas, P. S. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90652-1 · Cited by 532 · see citing works
Stoddard, M. F., Dawkins, P. R., Prince, C. R., & Ammash, N. M. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)00396-8 · Cited by 531 · see citing works
Melenovský, V., Hwang, S., Redfield, M. M., Zakeri, R., Lin, G., & Borlaug, B. A. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.001667 · Cited by 527 · see citing works
Goldstein, R. E., Boccuzzi, S. J., Cruess, D., & Nattel, S. (1991) · Circulation · doi:10.1161/01.cir.83.1.52 · Cited by 521 · see citing works
ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
Anderson, J. L., Heidenreich, P. A., Barnett, P. G., Creager, M. A., Fonarow, G. C., Gibbons, R. J., Halperin, J. L., Hlatky, M. A., Jacobs, A. K., Mark, D. B., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000042 · Cited by 520 · see citing works
Self-citationMinimizing Ventricular Pacing to Reduce Atrial Fibrillation in Sinus-Node Disease
Sweeney, M. O., Bank, A. J., Nsah, E., Koullick, M., Zeng, Q. C., Hettrick, D. A., Sheldon, T., & Lamas, G. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071880 · Cited by 518 · see citing works
Thyroid Hormones and Cardiovascular Function and Diseases
Razvi, S., Jabbar, A., Pingitore, A., Danzi, S., Biondi, B., Klein, I., Peeters, R., Zaman, A., & Iervasi, G. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.045 · Cited by 515 · see citing works
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery
Arsenault, K. A., Yusuf, A. M., Crystal, E., Healey, J. S., Morillo, C. A., Nair, G. M., & Whitlock, R. P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003611.pub3 · Cited by 514 · see citing works
Wan, Y., Heneghan, C., Perera, R., Roberts, N., Hollowell, J., Glasziou, P., Bankhead, C., & Xu, Y. (2008) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.796185 · Cited by 514 · see citing works
DEEDWANIA, P. C., Singh, B. N., Ellenbogen, K. A., Fisher, S. G., Fletcher, R. D., & Singh, S. N. (1998) · Circulation · doi:10.1161/01.cir.98.23.2574 · Cited by 505 · see citing works
Hunter, R. J., Berriman, T., Diab, I. G., Kamdar, R., Richmond, L., Baker, V., Goromonzi, F., Sawhney, V., Duncan, E. R., Page, S. P., et al. (2014) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.113.000806 · Cited by 504 · see citing works
Stabile, G., Bertaglia, E., Senatore, G., Simone, A. D., Zoppo, F., Donnici, G., Turco, P., Pascotto, P., FAZZARI, M., & Vitale, D. F. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi583 · Cited by 502 · see citing works
The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation
Tedrow, U. B., Conen, D., Ridker, P. M., Cook, N. R., Koplan, B. A., Manson, J. E., Buring, J. E., & Albert, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.029 · Cited by 500 · see citing works
Munger, T. M., Packer, D. L., Hammill, S. C., Feldman, B. J., Bailey, K. R., Ballard, D. J., Holmes, D. R., & Gersh, B. J. (1993) · Circulation · doi:10.1161/01.cir.87.3.866 · Cited by 500 · see citing works
Healey, J. S., Crystal, E., Lamy, A., Teoh, K., Semelhago, L., Hohnloser, S. H., Cybulsky, I., Abouzahr, L., Sawchuck, C., Carroll, S., et al. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.09.054 · Cited by 496 · see citing works
Pedersen, O. D., Bagger, H., Keller, N., Marchant, B., Køber, L., & Torp-Pedersen, C. (2001) · Circulation · doi:10.1161/01.cir.104.3.292 · Cited by 496 · see citing works
Siontis, K. C., Zhang, X., Eckard, A., Bhave, N. M., Schaubel, D. E., He, K., Tilea, A. M., Stack, A. G., Balkrishnan, R., Yao, X., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035418 · Cited by 496 · see citing works
Self-citationAblation Versus Drug Therapy for Atrial Fibrillation in Heart Failure
Packer, D. L., Piccini, J. P., Monahan, K. H., Al‐Khalidi, H. R., Silverstein, A. P., Noseworthy, P. A., Poole, J. E., Bahnson, T. D., Lee, K. L., Mark, D. B., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050991 · Cited by 493 · see citing works
Self-citationWalkey, A. J., Wiener, R. S., Ghobrial, J. M., Curtis, L. H., & Benjamin, E. J. (2011) · JAMA · doi:10.1001/jama.2011.1615 · Cited by 490 · see citing works
Self-citationRoden, D. M., Woosley, R. L., & Primm, R. K. (1986) · American Heart Journal · doi:10.1016/0002-8703(86)90010-4 · Cited by 489 · see citing works
Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation
Guo, Y., Wang, H., Zhang, H., Liu, T., Liang, Z., Xia, Y., Yan, L., Xing, Y., Shi, H., Li, S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.019 · Cited by 489 · see citing works
Stambler, B. S., Wood, M. A., Ellenbogen, K. A., Perry, K. T., Wakefield, L. K., & VanderLugt, J. T. (1996) · Circulation · doi:10.1161/01.cir.94.7.1613 · Cited by 485 · see citing works
Jones, D. G., Haldar, S. K., Hussain, W., Sharma, R., Francis, D. P., Rahman-Haley, S. L., McDonagh, T. A., Underwood, S. R., Markides, V., & Wong, T. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.069 · Cited by 481 · see citing works
Flagged first, then by citations
20 of the 1396 references couldn’t be matched to a known paper.
Research works printed but not linked: 250
- [1]Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (US). Clinical Practice Guidelines We Can Trust. National Academies Press; 2011.
- [2]Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (US). Finding What Works in Healthcare: Standards for Systematic Reviews. National Academies Press; 2011. 24983062
- [26]Schnabel RB, Yin X, Gona P, 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015; 386: 154– 162. 25960110 PMC4553037
- [91]Mou L, Norby FL, Chen LY, Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol. 2018; 11: e006350. 30002066 PMC6053683
- [1]Haissaguerre M, Jais P, Shah DC, Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998; 339: 659– 666. 9725923
- [1]Haissaguerre M, Jais P, Shah DC, Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998; 339: 659– 666. 9725923
- [5]Voigt N, Trausch A, Knaut M, Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol. 2010; 3: 472– 480. 20657029 PMC5832445
- [1]Lubitz SA, Yin X, Fontes JD, Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010; 304: 2263– 2269. 21076174 PMC3073054
- [5]Roselli C, Chaffin MD, Weng LC, Multi-ethnic genome-wide association study for atrial fibrillation. Nat Genet. 2018; 50: 1225– 1233. 29892015 PMC6136836
- [3]Lunde ED, Nielsen PB, Riahi S, Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review. Expert Rev Cardiovasc Ther. 2018; 16: 857– 873. 30293472
- [11]Kunneman M, Branda ME, Hargraves IG, Assessment of shared decision-making for stroke prevention in patients with atrial fibrillation: a randomized clinical trial. JAMA Intern Med. 2020; 180: 1215– 1224. 32897386 PMC7372497
- [2]Alonso A, Krijthe BP, Aspelund T, Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013; 2: e000102. 23537808 PMC3647274
- [5]Shang W, Li L, Huang S, Chronic kidney disease and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies. PLoS One. 2016; 11: e0155581. 27175779 PMC4866731
- [16]Perez MV, Mahaffey KW, Hedlin H, Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019; 381: 1909– 1917. 31722151 PMC8112605
- [4]Aune D, Schlesinger S, Norat T, Tobacco smoking and the risk of atrial fibrillation: a systematic review and meta-analysis of prospective studies. Eur J Prev Cardiol. 2018; 25: 1437– 1451. 29996680
- [5]Aune D, Feng T, Schlesinger S, Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018; 32: 501– 511. 29653902
- [6]Soliman EZ, Rahman AF, Zhang ZM, Effect of intensive blood pressure lowering on the risk of atrial fibrillation. Hypertension. 2020; 75: 1491– 1496. 32362229 PMC7225060
- [7]Alonso A, Krijthe BP, Aspelund T, Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013; 2: e000102. 23537808 PMC3647274
- [8]Himmelreich JCL, Veelers L, Lucassen WAM, Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis. Europace. 2020; 22: 684– 694. 32011689 PMC7526764
- [9]Roselli C, Chaffin MD, Weng LC, Multi-ethnic genome-wide association study for atrial fibrillation. Nat Genet. 2018; 50: 1225– 1233. 29892015 PMC6136836
- [10]Huxley RR, Lopez FL, Folsom AR, Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123: 1501– 1508. 21444879 PMC3181498
- [15]Mishima RS, Verdicchio CV, Noubiap JJ, Self-reported physical activity and atrial fibrillation risk: a systematic review and meta-analysis. Heart Rhythm. 2021; 18: 520– 528. 33348059
- [23]Newman W, Parry-Williams G, Wiles J, Risk of atrial fibrillation in athletes: a systematic review and meta-analysis. Br J Sports Med. 2021; 55: 1233– 1238. 34253538
- [25]Marcus GM, Vittinghoff E, Whitman IR, Acute consumption of alcohol and discrete atrial fibrillation events. Ann Intern Med. 2021; 174: 1503– 1509. 34461028
- [31]Lu Y, Guo Y, Lin H, Genetically determined tobacco and alcohol use and risk of atrial fibrillation. BMC Med Genomics. 2021; 14: 73. 33750369 PMC7944892
- [1]Abed HS, Wittert GA, Leong DP, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013; 310: 2050– 2060. 24240932
- [2]Pathak RK, Middeldorp ME, Meredith M, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015; 65: 2159– 2169. 25792361
- [4]Middeldorp ME, Pathak RK, Meredith M, PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018; 20: 1929– 1935. 29912366
- [10]Di Benedetto L, Michels G, Luben R, Individual and combined impact of lifestyle factors on atrial fibrillation in apparently healthy men and women: the EPIC-Norfolk prospective population study. Eur J Prev Cardiol. 2018; 25: 1374– 1383. 29863403
- [13]Donnellan E, Wazni O, Kanj M, Outcomes of atrial fibrillation ablation in morbidly obese patients following bariatric surgery compared with a nonobese cohort. Circ Arrhythm Electrophysiol. 2019; 12: e007598. 31610693
- [14]Donnellan E, Wazni OM, Kanj M, Association between pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation. Europace. 2019; 21: 1476– 1483. 31304532
- [15]Donnellan E, Wazni OM, Elshazly M, Impact of bariatric surgery on atrial fibrillation type. Circ Arrhythm Electrophysiol. 2020; 13: e007626. 31940441
- [17]Mohanty S, Mohanty P, Natale V, Impact of weight loss on ablation outcome in obese patients with longstanding persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2018; 29: 246– 253. 29171116
- [1]Hegbom F, Stavem K, Sire S, Effects of short-term exercise training on symptoms and quality of life in patients with chronic atrial fibrillation. Int J Cardiol. 2007; 116: 86– 92. 16815571
- [2]Malmo V, Nes BM, Amundsen BH, Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. Circulation. 2016; 133: 466– 473. 26733609
- [3]Elliott AD, Verdicchio CV, Mahajan R, An exercise and physical activity program in patients with atrial fibrillation: the ACTIVE-AF randomized controlled trial. J Am Coll Cardiol EP. 2023; 9: 455– 465. 36752479
- [4]Pathak RK, Elliott A, Middeldorp ME, Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol. 2015; 66: 985– 996. 26113406
- [5]Oesterle A, Giancaterino S, Van Noord MG, Effects of supervised exercise training on atrial fibrillation: a meta-analysis of randomized controlled trials. J Cardiopulm Rehabil Prev. 2022; 42: 258– 265. 35235540
- [6]Osbak PS, Mourier M, Kjaer A, A randomized study of the effects of exercise training on patients with atrial fibrillation. Am Heart J. 2011; 162: 1080– 1087. 22137082
- [10]Andersen K, Farahmand B, Ahlbom A, Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J. 2013; 34: 3624– 3631. 23756332
- [1]Arnett DK, Blumenthal RS, Albert MA, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 74: e177– e232. 30894318 PMC7685565
- [1]Voskoboinik A, Kalman JM, De Silva A, Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med. 2020; 382: 20– 28. 31893513
- [3]Marcus GM, Modrow MF, Schmid CH, Individualized studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical trial. JAMA Cardiol. 2022; 7: 167– 174. 34775507 PMC8591553
- [4]Marcus GM, Vittinghoff E, Whitman IR, Acute consumption of alcohol and discrete atrial fibrillation events. Ann Intern Med. 2021; 174: 1503– 1509. 34461028
- [5]Abed HS, Wittert GA, Leong DP, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013; 310: 2050– 2060. 24240932
- [6]Pathak RK, Middeldorp ME, Lau DH, Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014; 64: 2222– 2231. 25456757
- [7]Pathak RK, Middeldorp ME, Meredith M, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015; 65: 2159– 2169. 25792361
- [8]Middeldorp ME, Pathak RK, Meredith M, PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018; 20: 1929– 1935. 29912366
- [2]Marcus GM, Modrow MF, Schmid CH, Individualized Studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical trial. JAMA Cardiol. 2022; 7: 167– 174. 34775507 PMC8591553
- [12]Abed HS, Wittert GA, Leong DP, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013; 310: 2050– 2060. 24240932
- [13]Pathak RK, Middeldorp ME, Meredith M, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015; 65: 2159– 2169. 25792361
- [3]Donnellan E, Aagaard P, Kanj M, Association between pre-ablation glycemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation. J Am Coll Cardiol EP. 2019; 5: 897– 903. 31439289
- [1]Neefs J, van den Berg NW, Limpens J, Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2017; 231: 155– 161. 28062142
- [2]Steinberg JS, Shabanov V, Ponomarev D, Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: the ERADICATE-AF randomized clinical trial. JAMA. 2020; 323: 248– 255. 31961420 PMC6990678
- [3]Pathak RK, Middeldorp ME, Lau DH, Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014; 64: 2222– 2231. 25456757
- [5]Pinho-Gomes AC, Azevedo L, Copland E, Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: an individual participant data meta-analysis. PLoS Med. 2021; 18: e1003599. 34061831 PMC8168843
- [8]Parkash R, Wells GA, Sapp JL, Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]). Circulation. 2017; 135: 1788– 1798. 28228428
- [9]Soliman EZ, Rahman AF, Zhang ZM, Effect of intensive blood pressure lowering on the risk of atrial fibrillation. Hypertension. 2020; 75: 1491– 1496. 32362229 PMC7225060
- [11]Pathak RK, Middeldorp ME, Meredith M, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015; 65: 2159– 2169. 25792361
- [6]Li X, Zhou X, Xu X, Effects of continuous positive airway pressure treatment in obstructive sleep apnea patients with atrial fibrillation: a meta-analysis. Medicine (Baltimore). 2021; 100: e25438. 33847645 PMC8051983
- [7]Yang Y, Ning Y, Wen W, CPAP is associated with decreased risk of AF recurrence in patients with OSA, especially those younger and slimmer: a meta-analysis. J Interv Card Electrophysiol. 2020; 58: 369– 379. 32472281
- [8]Congrete S, Bintvihok M, Thongprayoon C, Effect of obstructive sleep apnea and its treatment of atrial fibrillation recurrence after radiofrequency catheter ablation: a meta-analysis. J Evid Based Med. 2018; 11: 145– 151. 30091301
- [9]Deng F, Raza A, Guo J. Treating obstructive sleep apnea with continuous positive airway pressure reduces risk of recurrent atrial fibrillation after catheter ablation: a meta-analysis. Sleep Med. 2018; 46: 5– 11. 29773211
- [10]Qureshi WT, Nasir UB, Alqalyoobi S, Meta-analysis of continuous positive airway pressure as a therapy of atrial fibrillation in obstructive sleep apnea. Am J Cardiol. 2015; 116: 1767– 1773. 26482182
- [11]Szymanski FM, Filipiak KJ, Platek AE, Presence and severity of obstructive sleep apnea and remote outcomes of atrial fibrillation ablations - a long-term prospective, cross-sectional cohort study. Sleep Breath. 2015; 19: 849– 856. 25566942 PMC4559085
- [12]Caples SM, Mansukhani MP, Friedman PA, The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: a randomized controlled trial. Int J Cardiol. 2019; 278: 133– 136. 30522886
- [13]Traaen GM, Aakeroy L, Hunt TE, Effect of continuous positive airway pressure on arrhythmia in atrial fibrillation and sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med. 2021; 204: 573– 582. 33938787
- [22]Hunt TE, Traaen GM, Aakeroy L, Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: a randomized controlled trial. Heart Rhythm. 2022; 19: 1433– 1441. 35716856
- [1]Voskoboinik A, Kalman JM, De Silva A, Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med. 2020; 382: 20– 28. 31893513
- [2]Abed HS, Wittert GA, Leong DP, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013; 310: 2050– 2060. 24240932
- [3]Rienstra M, Hobbelt AH, Alings M, Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J. 2018; 39: 2987– 2996. 29401239
- [11]Hlatky MA, Greenland P, Arnett DK, Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009; 119: 2408– 2416. 19364974 PMC2956982
- [24]Rao MP, Halvorsen S, Wojdyla D, Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. J Am Heart Assoc. 2015; 4: e002015. 26627878 PMC4845276
- [3]Steinberg BA, Hellkamp AS, Lokhnygina Y, Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J. 2015; 36: 288– 296. 25209598 PMC4313363
- [4]Chao TF, Lip GYH, Lin YJ, Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost. 2018; 118: 768– 777. 29510426
- [1]Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139– 1151. 19717844
- [2]Patel MR, Mahaffey KW, Garg J, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883– 891. 21830957
- [3]Granger CB, Alexander JH, McMurray JJ, Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981– 992. 21870978
- [4]Giugliano RP, Ruff CT, Braunwald E, Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093– 2104. 24251359
- [14]Singer DE, Chang Y, Borowsky LH, A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013; 2: e000250. 23782923 PMC3698792
- [15]Gage BF, Waterman AD, Shannon W, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864– 2870. 11401607
- [23]Kido K Atrial fibrillation/atrial flutter: stroke prevention. In: CardSAP 2021; Book 2. Arrhythmias and Thrombosis. American College of Clinical Pharmacy; 2021: 32– 33.
- [13]Buck BH, Hill MD, Quinn FR, Effect of implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation detection in patients with ischemic stroke: the per diem randomized clinical trial. JAMA. 2021; 325: 2160– 2168. 34061146 PMC8170545
- [8]Eckman MH, Singer DE, Rosand J, Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011; 4: 14– 21. 21139092 PMC3058150
- [9]Gutiérrez EM, Castaño M, Gualis J, Beneficial effect of left atrial appendage closure during cardiac surgery: a meta-analysis of 280 585 patients. Eur J Cardiothorac Surg. 2020; 57: 252– 262. 31711150
- [22]Kido K Atrial fibrillation/atrial flutter: stroke prevention. In: CardSAP 2021; Book 2. Arrhythmias and Thrombosis. American College of Clinical Pharmacy; 2021: 32– 33.
- [7]Holmes DR Jr, Kar S, Price MJ, Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014; 64: 1– 12. 24998121
- [27]Reddy VY, Doshi SK, Kar S, 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017; 70: 2964– 2975. 29103847
- [24]Granger CB, Alexander JH, McMurray JJ, Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981– 992. 21870978
- [2]Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139– 1151. 19717844
- [3]Patel MR, Mahaffey KW, Garg J, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883– 891. 21830957
- [4]Granger CB, Alexander JH, McMurray JJ, Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981– 992. 21870978
- [5]Giugliano RP, Ruff CT, Braunwald E, Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093– 2104. 24251359
- [6]López-López JA, Sterne JAC, Thom HHZ, Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017; 359: j5058. 29183961 PMC5704695
- [8]Ruff CT, Giugliano RP, Braunwald E, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383: 955– 962. 24315724
- [13]Brokmeier H, Kido K. Off-label use for direct oral anticoagulants: valvular atrial fibrillation, heart failure, left ventricular thrombus, superficial vein thrombosis, pulmonary hypertension-a systematic review. Ann Pharmacother. 2021; 55: 995– 1009. 33148014 PMC8371988
- [6]Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857– 867. 17577005
- [8]Sanna T, Diener HC, Passman RS, Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014; 370: 2478– 2486. 24963567
- [17]Kirchhof P, Camm AJ, Goette A, Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020; 383: 1305– 1316. 32865375
- [18]Van Gelder IC, Groenveld HF, Crijns HJGM, Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010; 362: 1363– 1373. 20231232
- [12]Connolly SJ, Camm AJ, Halperin JL, Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011; 365: 2268– 2276. 22082198
- [13]Ulimoen SR, Enger S, Carlson J, Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol. 2013; 111: 225– 230. 23111138
- [14]Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J. 2009; 85: 303– 312. 19528305
- [14]Brignole M, Gianfranchi L, Menozzi C, Atrioventricular junction ablation and pacemaker therapy versus drug treatment in atrial fibrillation. Cardiol Rev. 1998; 15: 49– 53.
- [16]D H, Novak P, O S. Survival of dual chamber pacing post atrioventricular nodal ablation in patients with atrial fibrillation. Heart Rhythm. 2009; 6: S406– S407.
- [1]Santhanakrishnan R, Wang N, Larson MG, Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016; 133: 484– 492. 26746177 PMC4738087
- [10]Van Gelder IC, Groenveld HF, Crijns HJ, Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010; 362: 1363– 1373. 20231232
- [11]Andrade JG, Wells GA, Deyell MW, Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021; 384: 305– 315. 33197159
- [12]Kirchhof P, Camm AJ, Goette A, Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020; 383: 1305– 1316. 32865375
- [13]Kim D, Yang PS, You SC, Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ. 2021; 373: n991. 33975876 PMC8111568
- [25]Pathak RK, Middeldorp ME, Meredith M, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015; 65: 2159– 2169. 25792361
- [56]Hsu LF, Jaïs P, Sanders P, Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004; 351: 2373– 2383. 15575053
- [9]Aryana A, Singh SK, Singh SM, Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. Heart Rhythm. 2015; 12: 1431– 1437. 25998141
- [13]Boersma LV, Ince H, Kische S, Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017; 14: 1302– 1308. 28577840
- [23]Lip GY, Gitt AK, Le Heuzey JY, Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). Am J Cardiol. 2014; 113: 480– 484. 24332698
- [24]Airaksinen KE, Grönberg T, Nuotio I, Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013; 62: 1187– 1192. 23850908
- [1]Dankner R, Shahar A, Novikov I, Treatment of stable atrial fibrillation in the emergency department: a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management. Cardiology. 2009; 112: 270– 278. 18815445
- [3]Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J. 1967; 29: 469– 489. 6029120 PMC487824
- [6]Crijns HJ, Weijs B, Fairley AM, Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study. Int J Cardiol. 2014; 172: 588– 594. 24556445
- [11]Stiell IG, Clement CM, Brison RJ, Variation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departments. Ann Emerg Med. 2011; 57: 13– 21. 20864213
- [12]Hindricks G, Potpara T, Dagres N, 2020 ESC guidelines for the diagnosis and management of atrial fibrillation. Developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42: 373– 498. 32860505
- [13]Hernandez-Madrid A, Svendsen JH, Lip GY, Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey. Europace. 2013; 15: 915– 918. 23709570
- [14]Pisters R, Nieuwlaat R, Prins MH, Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace. 2012; 14: 666– 674. 22223715
- [19]Brandes A, Crijns H, Rienstra M, Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure. Europace. 2020; 22: 1149– 1161. 32337542 PMC7399700
- [1]Dankner R, Shahar A, Novikov I, Treatment of stable atrial fibrillation in the emergency department: a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management. Cardiology. 2009; 112: 270– 278. 18815445
- [20]Oral H, Souza JJ, Michaud GF, Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med. 1999; 340: 1849– 1854. 10369847
- [1]Pedersen OD, Bagger H, Keller N, Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) substudy. Circulation. 2001; 104: 292– 296. 11457747
- [2]Deedwania PC, Singh BN, Ellenbogen K, Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998; 98: 2574– 2579. 9843465
- [12]Brembilla-Perrot B, Houriez P, Beurrier D, Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias. Int J Cardiol. 2001; 80: 7– 15. 11532541
- [15]Hohnloser SH, Crijns HJ, van Eickels M, Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009; 360: 668– 678. 19213680
- [16]Singh S, Zoble RG, Yellen L, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation. 2000; 102: 2385– 2390. 11067793
- [17]Singh BN, Singh SN, Reda DJ, Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352: 1861– 1872. 15872201
- [28]Kober L, Torp-Pedersen C, McMurray JJ, Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358: 2678– 2687. 18565860
- [1]Singh S, Zoble RG, Yellen L, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation. 2000; 102: 2385– 2390. 11067793
- [2]Abraham JM, Saliba WI, Vekstein C, Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol. 2015; 8: 772– 776. 26063741
- [6]Pedersen OD, Bagger H, Keller N, Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 2001; 104: 292– 296. 11457747
- [9]Alboni P, Botto GL, Baldi N, Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004; 351: 2384– 2391. 15575054
- [10]Andrade JG, MacGillivray J, Macle L, Clinical effectiveness of a systematic "pill-in-the-pocket" approach for the management of paroxysmal atrial fibrillation. Heart Rhythm. 2018; 15: 9– 16. 29304952
- [12]Azpitarte J, Alvarez M, Baún O, Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J. 1997; 18: 1649– 1654. 9347277
- [13]Markman TM, Jarrah AA, Tian Y, Safety of pill-in-the-pocket class 1C antiarrhythmic drugs for atrial fibrillation. J Am Coll Cardiol EP. 2022; 8: 1515– 1520. 36543501
- [15]Singh BN, Singh SN, Reda DJ, Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352: 1861– 1872. 15872201
- [4]Hamilton D Sr, Nandkeolyar S, Lan H, Amiodarone: a comprehensive guide for clinicians. Am J Cardiovasc Drugs. 2020; 20: 549– 558. 32166725
- [9]Tisdale JE, Chung MK, Campbell KB, Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation. 2020; 142: e214– e233. 32929996
- [11]Singh S, Zoble RG, Yellen L, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation. 2000; 102: 2385– 2390. 11067793
- [12]Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999; 341: 857– 865. 10486417
- [16]Ellenbogen KA, Stambler BS, Wood MA, Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996; 28: 130– 136. 8752805
- [21]Stambler BS, Wood MA, Ellenbogen KA, Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996; 94: 1613– 1621. 8840852
- [23]Vardas PE, Kochiadakis GE, Igoumenidis NE, Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest. 2000; 117: 1538– 1545. 10858380
- [30]Kochiadakis GE, Igoumenidis NE, Solomou MC, Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther. 1998; 12: 75– 81. 9607135
- [31]Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation. 1997; 96: 4298– 4306. 9416896
- [34]Singh BN, Singh SN, Reda DJ, Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352: 1861– 1872. 15872201
- [22]Neefs J, van den Berg NW, Limpens J, Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2017; 231: 155– 161. 28062142
- [27]Kowey PR, Reiffel JA, Ellenbogen KA, Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010; 304: 2363– 2372. 21078810
- [30]Gencer B, Djousse L, Al-Ramady OT, Effect of long-term marine -3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021; 144: 1981– 1990. 34612056 PMC9109217
- [12]Andrade JG, Wells GA, Deyell MW, Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021; 384: 305– 315. 33197159
- [18]Pérez FJ, Schubert CM, Parvez B, Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis. Circ Arrhythm Electrophysiol. 2009; 2: 393– 401. 19808495
- [31]Disertori M, Lombardi F, Barlera S, Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. Am Heart J. 2011; 162: 382– 389. 21835301
- [32]Senoo K, Suzuki S, Otsuka T, Progression to the persistent form in asymptomatic paroxysmal atrial fibrillation. Circ J. 2014; 78: 1121– 1126. 24553324
- [35]Yang WY, Du X, Fawzy AM, Associations of atrial fibrillation progression with clinical risk factors and clinical prognosis: a report from the Chinese Atrial Fibrillation Registry study. J Cardiovasc Electrophysiol. 2021; 32: 333– 341. 33269504
- [39]Holmqvist F, Kim S, Steinberg BA, Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart. 2015; 101: 894– 899. 25732748 PMC4453487
- [40]January CT, Wann LS, Alpert JS, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64: e1– e76. 24685669
- [46]Mark DB, Anstrom KJ, Sheng S, Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321: 1275– 1285. 30874716 PMC6450275
- [47]Miura K, Ikemura N, Kimura T, Treatment strategies and subsequent changes in the patient-reported quality-of-life among elderly patients with atrial fibrillation. Am Heart J. 2020; 222: 83– 92. 32028139
- [59]Willems S, Borof K, Brandes A, Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2022; 43: 1219– 1230. 34447995 PMC8934687
- [1]Packer DL, Mark DB, Robb RA, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321: 1261– 1274. 30874766 PMC6450284
- [5]Kirchhof P, Camm AJ, Goette A, Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020; 383: 1305– 1316. 32865375
- [9]Chew DS, Jones KA, Loring Z, Diagnosis-to-ablation time predicts recurrent atrial fibrillation and rehospitalization following catheter ablation. Heart Rhythm O2. 2022; 3: 23– 31. 35243432 PMC8859793
- [12]Di Biase L, Mohanty P, Mohanty S, Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016; 133: 1637– 1644. 27029350
- [13]Marrouche NF, Brachmann J, Andresen D, Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378: 417– 427. 29385358
- [15]Di Biase L, Burkhardt JD, Mohanty P, Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2010; 122: 109– 118. 20606120
- [16]Calkins H, Hindricks G, Cappato R, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017; 14: e275– e444. 28506916 PMC6019327
- [1]Packer DL, Mark DB, Robb RA, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321: 1261– 1274. 30874766 PMC6450284
- [5]Calkins H, Reynolds MR, Spector P, Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009; 2: 349– 361. 19808490
- [10]Blomström-Lundqvist C, Gizurarson S, Schwieler J, Effect of Catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA. 2019; 321: 1059– 1068. 30874754 PMC6439911
- [11]Packer DL, Kowal RC, Wheelan KR, Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013; 61: 1713– 1723. 23500312
- [18]Jais P, Cauchemez B, Macle L, Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008; 118: 2498– 2505. 19029470
- [8]Reynolds MR, Allison JS, Natale A, A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. J Am Coll Cardiol EP. 2018; 4: 580– 588.
- [11]Packer DL, Mark DB, Robb RA, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321: 1261– 1274. 30874766 PMC6450284
- [12]Steinberg BA, Hellkamp AS, Lokhnygina Y, Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J. 2015; 36: 288– 296. 25209598 PMC4313363
- [13]Al-Khatib SM, Thomas L, Wallentin L, Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013; 34: 2464– 2471. 23594592
- [17]Marrouche NF, Brachmann J, Andresen D, Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378: 417– 427. 29385358
- [18]Piccini JP, Sinner MF, Greiner MA, Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. Circulation. 2012; 126: 2200– 2207. 23019293 PMC3500836
- [19]Calkins H, Hindricks G, Cappato R, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017; 14: e275– e444. 28506916 PMC6019327
- [4]Campbell ML, Larson J, Farid T, Sex-based differences in procedural complications associated with atrial fibrillation catheter ablation: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2020; 31: 3176– 3186. 32966681
- [5]Russo AM, Zeitler EP, Giczewska A, Association between sex and treatment outcomes of atrial fibrillation ablation versus drug therapy: results from the CABANA trial. Circulation. 2021; 143: 661– 672. 33499668 PMC8032462
- [4]Noseworthy PA, Yao X, Deshmukh AJ, Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation. J Am Heart Assoc. 2015; 4: e002597. 26541393 PMC4845220
- [5]Santhanakrishnan R, Wang N, Larson MG, Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016; 133: 484– 492. 26746177 PMC4738087
- [1]Rillig A, Magnussen C, Ozga AK, Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation. 2021; 144: 845– 858. 34328366 PMC8456351
- [4]Di Biase L, Mohanty P, Mohanty S, Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016; 133: 1637– 1644. 27029350
- [8]MacDonald MR, Connelly DT, Hawkins NM, Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart. 2011; 97: 740– 747. 21051458
- [9]Marrouche NF, Brachmann J, Andresen D, Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378: 417– 427. 29385358
- [11]Parkash R, Wells GA, Rouleau J, Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial. Circulation. 2022; 145: 1693– 1704. 35313733
- [13]Turagam MK, Garg J, Whang W, Catheter ablation of atrial fibrillation in patients with heart failure: a meta-analysis of randomized controlled trials. Ann Intern Med. 2019; 170: 41– 50. 30583296
- [14]Packer DL, Piccini JP, Monahan KH, Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation. 2021; 143: 1377– 1390. 33554614 PMC8030730
- [16]Khand AU, Rankin AC, Martin W, Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003; 42: 1944– 1951. 14662257
- [17]Kotecha D, Bunting KV, Gill SK, Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA. 2020; 324: 2497– 2508. 33351042 PMC7756234
- [18]Clemo HF, Wood MA, Gilligan DM, Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol. 1998; 81: 594– 598. 9514456
- [19]Delle Karth G, Geppert A, Neunteufl T, Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001; 29: 1149– 1153. 11395591
- [20]Brignole M, Menozzi C, Gianfranchi L, Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation. 1998; 98: 953– 960. 9737514
- [21]Kay GN, Ellenbogen KA, Giudici M, The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. J Interv Card Electrophysiol. 1998; 2: 121– 135. 9870004
200 of 250 shown
Cited by
Sorted by citations
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.009 · Cited by 652 · see citing works
Self-citation2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K., Evanovich, L., Ferrari, V. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.014 · Cited by 418 · see citing works
Self-citationMaddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362 · see citing works
Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.013 · Cited by 294 · see citing works
Drazner, M. H., Bozkurt, B., Cooper, L. T., Aggarwal, N. R., Basso, C., Bhave, N. M., Caforio, A. L. P., Ferreira, V. M., Heidecker, B., Kontorovich, A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.080 · Cited by 278 · see citing works
Left Atrial Appendage Closure after Ablation for Atrial Fibrillation
Wazni, O. M., Saliba, W. I., Nair, D. G., Marijon, É., Schmidt, B., Hounshell, T., Ebelt, H., Skurk, C., Oza, S. R., Patel, C. P., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2408308 · Cited by 253 · see citing works
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280 · see citing works
Thompson, A., Fleischmann, K. E., Smilowitz, N. R., Fuentes, L. D. L., Mukherjee, D., Aggarwal, N. R., Ahmad, F. S., Allen, R. B., Altin, S. E., Auerbach, A. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.013 · Cited by 251 · see citing works
Doehner, W., Boriani, G., Potpara, T., Blomström‐Lundqvist, C., PASSMAN, R. S., Sposato, L. A., Dobrev, D., Freedman, B., Gelder, I. C. V., Glotzer, T. V., et al. (2025) · EP Europace · doi:10.1093/europace/euaf019 · Cited by 144 · see citing works
Vinter, N., Cordsen, P., Johnsen, S. P., Stærk, L., Benjamin, E. J., Frost, L., & Trinquart, L. (2024) · BMJ · doi:10.1136/bmj-2023-077209 · Cited by 121 · see citing works
Self-citation2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease
Gurvitz, M. Z., Krieger, E. V., Fuller, S., Davis, L. L., Kittleson, M. M., Aboulhosn, J., Bradley, E. A., Buber, J., Daniels, C. J., Dimopoulos, K., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.006 · Cited by 132 · see citing works
Self-citationCasselman, F. P. A., Lance, M. D., Ahmed, A. B., Ascari, A., Blanco-Morillo, J., Bolliger, D., Eid, M., Erdoes, G., Haumann, R. G., Jeppsson, A., et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae352 · Cited by 115 · see citing works
Reddy, V. Y., Gerstenfeld, E. P., Schmidt, B., Andrade, J. G., Nair, D. G., Natale, A., Saliba, W. I., Sommer, P., Metzner, A., Verma, A., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.074485 · Cited by 109 · see citing works
Self-citationPulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation
Reddy, V. Y., Mansour, M., Calkins, H. G., d’Ávila, A., Chinitz, L. A., Woods, C. E., Gupta, S. K., Kim, J., ELDADAH, Z. A., Pickett, R. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.001 · Cited by 101 · see citing works
Self-citationLeft Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation
Doshi, S. K., Kar, S., Nair, D. G., Waggoner, T. E., Agarwal, H., Moussavian, M., کاشانی, ا., Oza, S. R., Feldman, L. A., Sadhu, A. K., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2517213 · Cited by 88 · see citing works
Svennberg, E., Han, J. K., Caiani, E. G., Engelhardt, S., Ernst, S., Friedman, P. A., Garcia, R., Ghanbari, H., Hindricks, G., Man, S. H., et al. (2025) · EP Europace · doi:10.1093/europace/euaf071 · Cited by 92 · see citing works
Self-citationPulsed-field ablation versus thermal ablation for atrial fibrillation: A meta-analysis
de Campos, M. C. A. V., Moraes, V. R. Y., Daher, R. F., Micheleto, J. P. C., de Campos, L. A. V., Barros, G. F. A., de Oliveira, H. M., Barros, L. P., & Menezes, A. D. S. (2024) · Heart Rhythm O2 · doi:10.1016/j.hroo.2024.04.012 · Cited by 81 · see citing works
Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation
Lópes, R. D., Granger, C. B., WOJDYLA, D. M., McIntyre, W. F., Alings, M., Mani, T., Ramasundarahettige, C. F., Rivard, L., Atar, D., Birnie, D. H., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.002 · Cited by 76 · see citing works
Chu, M., Zhang, S., Gong, J., Yang, S., Yang, G., Sun, X., Wu, D., Xia, Y., Jiao, J., Peng, X., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03511-2 · Cited by 75 · see citing works
Pulmonary vein narrowing after pulsed field versus thermal ablation
MANSOUR, M. C., Gerstenfeld, E. P., Patel, C. P., Natale, A., Whang, W., Cuoco, F. A., Mountantonakis, S., Gibson, D. N., Harding, J. D., Holland, S. K., et al. (2024) · EP Europace · doi:10.1093/europace/euae038 · Cited by 64 · see citing works
Self-citationAnticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease
Rashedi, S., Keykhaei, M., Sato, A., Steg, P. G., Piazza, G., Eikelboom, J. W., Lópes, R. D., Bonaca, M. P., Yasuda, S., Ogawa, H., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.12.030 · Cited by 62 · see citing works
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90 · see citing works
Landmesser, U., Skurk, C., Tzikas, A., Falk, V., Reddy, V. Y., & Windecker, S. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae398 · Cited by 56 · see citing works
Pulsed Field Ablation for Persistent Atrial Fibrillation
Reddy, V. Y., Gerstenfeld, E. P., Schmidt, B., Nair, D., Natale, A., Saliba, W. I., Verma, A., Sommer, P., Metzner, A., Turagam, M. K., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.515 · Cited by 56 · see citing works
Self-citationTargeting the Substrate for Atrial Fibrillation
McCauley, M. D., Iacobellis, G., Li, N., Nattel, S., & Goldberger, J. J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.050 · Cited by 52 · see citing works
Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention
Lópes, R. D., Atlas, S. J., Go, A. S., Lubitz, S. A., McManus, D. D., Dolor, R. J., Chatterjee, R., Rothberg, M. B., Rushlow, D. R., Crosson, L. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.019 · Cited by 50 · see citing works
Casselman, F. P. A., Lance, M. D., Ahmed, A. B., Ascari, A., Blanco-Morillo, J., Bolliger, D., Eid, M., Erdoes, G., Haumann, R. G., Jeppsson, A., et al. (2024) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2024.10.006 · Cited by 44 · see citing works
Position Statement on Cardiac Computed Tomography Following Left Atrial Appendage Occlusion
Korsholm, K., Iriart, X., Saw, J., Wang, D. D., Berti, S. L., Galea, R., Freixa, X., Arzamendi, D., Backer, O. D., Kramer, A. D., et al. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2024.04.050 · Cited by 43 · see citing works
Satti, D. I., Karius, A. K., Chan, J. S. K., Isakadze, N., Yadav, R., Garg, K., Aronis, K. N., Marine, J. E., Berger, R. D., Calkins, H. G., et al. (2024) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.03.031 · Cited by 42 · see citing works
Gopinathannair, R., Olshansky, B., Chung, M. K., Gordon, S., Joglar, J. A., Marcus, G. M., Mar, P. L., Russo, A. M., Srivatsa, U. N., & Wan, E. Y. (2024) · Circulation · doi:10.1161/cir.0000000000001290 · Cited by 42 · see citing works
Self-citationDuytschaever, M. F., Račkauskas, G., Potter, T. J. R. D., Hansen, J., Knecht, S., Phlips, T., Vijgen, J. M., Scherr, D., Széplaki, G., Herendael, H. V., et al. (2024) · EP Europace · doi:10.1093/europace/euae088 · Cited by 40 · see citing works
Ortega‐Martorell, S., Olier, I., Ohlsson, M., Lip, G. Y. H., & on behalf of the TARGET Consortium (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2438-5671 · Cited by 40 · see citing works
Turagam, M. K., Neužil, P., Petrů, J., Funasako, M., Koruth, J. S., Skoda, J., Královec, Š., & Reddy, V. Y. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.04.102 · Cited by 39 · see citing works
Qiu, Y., Guo, H., Wang, S., Yang, S., Peng, X., Xiayao, D., Chen, R., Yang, J. M., Liu, J., Li, M., et al. (2024) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-024-02616-x · Cited by 39 · see citing works
5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial
Lakkireddy, D., Ellis, C. R., Thaler, D. E., Swarup, V., Gambhir, A., Hermiller, J. B., Nielsen‐Kudsk, J. E., Worthley, S. G., Nair, D. G., Schmidt, B., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.101 · Cited by 38 · see citing works
Reddy, V. Y., Anter, E., Peichl, P., Račkauskas, G., Petrů, J., Funasako, M., Koruth, J. S., Marinskis, G., Turagam, M. K., Aidietis, A., et al. (2024) · EP Europace · doi:10.1093/europace/euae090 · Cited by 35 · see citing works
State of the Art in Left Atrial Appendage Occlusion
Garg, J., Kabra, R., Gopinathannair, R., Biase, L. D., Wang, D. D., Saw, J., Hahn, R. T., Freeman, J. V., Ellis, C. R., & Lakkireddy, D. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.10.024 · Cited by 35 · see citing works
Self-citationGanatra, S., Barac, A., Armenian, S. H., Cambareri, C., Denlinger, C. S., Dent, S. F., Hayek, S. S., Ky, B., Leja, M. J., Lucas, C. H., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.10.018 · Cited by 35 · see citing works
Chang, H., Chan, Y., Kuo, L., & Chao, T. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2595-5575 · Cited by 33 · see citing works
Kostopoulos, G., & Effraimidis, G. (2024) · European Thyroid Journal · doi:10.1530/etj-23-0254 · Cited by 36 · see citing works
O’Brien, B., Campbell, N. G., Allen, E., Jamal, Z., Sturgess, J., Sanders, J., Opondo, C., Roberts, N., Aron, J., Maccaroni, M. R., et al. (2024) · JAMA · doi:10.1001/jama.2024.17888 · Cited by 33 · see citing works
Spooner, M. T., Messe, S. R., Chaturvedi, S., Do, M. M., Gluckman, T. J., Han, J. K., Russo, A. M., Saxonhouse, S. J., & Wiggins, N. B. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.100 · Cited by 37 · see citing works
Self-citationAtrial fibrillation catheter ablation, brain glymphatic function, and cognitive performance
Guo, J., Zhang, Z., Meng, X., Jing, J., Hu, Y., Yao, Y., Ding, L., Zheng, L., & Zhao, X. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf036 · Cited by 31 · see citing works
Pericardial Effusion After Left Atrial Appendage Closure
Galea, R., Bini, T., Krsnik, J. P., Touray, M., Temperli, F., Kassar, M., Papadis, A., Gloekler, S., Brugger, N., Madhkour, R., et al. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2024.01.310 · Cited by 29 · see citing works
Ortega‐Martorell, S., Olier, I., Ohlsson, M., & Lip, G. Y. H. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.12.003 · Cited by 29 · see citing works
Wolfes, J., Ellermann, C., Frommeyer, G., & Eckardt, L. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.12.018 · Cited by 27 · see citing works
McIntyre, W. F., Benz, A. P., Healey, J. S., Connolly, S. J., Yang, M., Lee, S. F., Field, T. S., Alings, M., Benezet‐Mazuecos, J., Boriani, G., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069903 · Cited by 26 · see citing works
Huang, H., Liu, J., Shuai, W., Jiang, C., Zhang, M., Qu, X.-F., Zheng, W., Yang, H. Y., Liu, F., Yu, B., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae532 · Cited by 24 · see citing works
Effects of Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction
Martens, P., Augusto, S. N., Erzeel, J., Pison, L., Müllens, W., & Tang, W. H. W. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.01.029 · Cited by 24 · see citing works
Saksena, S. V., Ken-Opurum, J., McKindley, D. S., Preblick, R., Rashkin, J., Aldaas, O. M., Sistla, S. S. S., & Hsu, J. C. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.11.020 · Cited by 23 · see citing works
The Heart-Brain-Metabolism Axis in Cardiovascular and Neurologic Disease
Tardo, D. T., Cortés‐Canteli, M., Fuster, V., Sachdev, P. S., & Kovacic, J. C. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1602 · Cited by 24 · see citing works
Petersen, J., Böning, H., Yildirim, S., Alassar, Y., Yıldırım, Y., Bazhanov, I., Sinning, C., Reichenspurner, H. C., & Pecha, S. (2024) · JTCVS Techniques · doi:10.1016/j.xjtc.2024.05.007 · Cited by 22 · see citing works
Aarnink, E. W., Ince, H., Kische, S., Pokushalov, E., Schmitz, T., Schmidt, B., Gori, T., Meincke, F., Protopopov, A. V., Betts, T. R., et al. (2024) · EP Europace · doi:10.1093/europace/euae188 · Cited by 22 · see citing works
A person-centred clinical approach to the multimorbid patient with COPD
Celli, B. R., Fabbri, L. M., Yohannes, A. M., Hawkins, N. M., Criner, G. J., Bon, J. M., Humbert, M. J. C., Jenkins, C. R., Pantoni, L., Papi, A. A., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.020 · Cited by 22 · see citing works
Reddy, V. Y., Gerstenfeld, E. P., Mountantonakis, S., Patel, C. P., Ellenbogen, K. A., Harding, J. D., Gibson, D., Natale, A., Waks, J. W., Calkins, H. G., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04246-4 · Cited by 22 · see citing works
Self-citationJia, S., Yin, Y., Mou, X., Zheng, J., Li, Z., Hu, T., Zhao, J., Lin, J., Song, J., Cheng, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02219-w · Cited by 22 · see citing works
Diet and risk of atrial fibrillation: a systematic review
Gawalko, M. M., Middeldorp, M. E., Saljic, A., Penders, J., Jespersen, T., Albert, C. M., Marcus, G. M., Wong, C. X. J., Sanders, P., & Linz, D. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae551 · Cited by 22 · see citing works
Self-citationLife-Threatening Arrhythmias in Patients With Takotsubo Syndrome
Vecchia, G. L., Buono, M. G. D., Sanna, T., Capecchi, P. L., Lazzerini, P. E., Golino, M., Kron, J., Rodriguez‐Miguelez, P., Pelargonio, G., & Abbate, A. (2024) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.03.034 · Cited by 22 · see citing works
Rosende, A., Romero, C. A., DiPette, D. J., Brettler, J. W., der Stuyft, P. V., Satheesh, G., Perel, P., Chapman, N., Moran, A. E., Schutte, A. E., et al. (2025) · Global Heart · doi:10.5334/gh.1428 · Cited by 21 · see citing works
Zhang, Z., Zheng, Y., He, W., Wei, J., Li, P., Zhong, G., & Jiang, Z. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14814 · Cited by 20 · see citing works
Titin-related familial dilated cardiomyopathy: factors associated with disease onset
Johnson, R., Fletcher, R. A., Peters, S. A., Ohanian, M., Soka, M. J., Smolnikov, A., Abihider, K. E., Ackerman, M. J., Ader, F., Akhtar, M. M., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf380 · Cited by 20 · see citing works
Bharaj, I. S., Brar, A. S., Kahlon, J., Singh, A., Hotwani, P., Kumar, V., Sohal, A., & Batta, A. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i6.106147 · Cited by 19 · see citing works
Virk, Z. M., El‐Harasis, M. A., Yoneda, Z. T., Anderson, K. C., Sun, L., Quintana, J. A., Murphy, B. S., Laws, J. L., Davogustto, G., O’Neill, M. J., et al. (2024) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.07.029 · Cited by 18 · see citing works
Jiang, X., Ling, J., Xiong, Q., Chen, W., Zou, L., & Ling, Z. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae033 · Cited by 18 · see citing works
Turagam, M. K., Neužil, P., Schmidt, B., Reichlin, T., Neven, K. G. E. J., Metzner, A., Hansen, J., Blaauw, Y., Maury, P., Arentz, T., et al. (2024) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.05.002 · Cited by 18 · see citing works
Galea, R., MARCO, F. D., Aminian, A., Meneveau, N. F., Chalkou, K., Anselme, F., Gräni, C., Franzone, A., Vranckx, P., Fischer, U., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.535 · Cited by 17 · see citing works
Pulsed-Field Ablation of Atrial Flutter
Demian, J., Younis, A., Wazni, O. M., Santangeli, P., Mdaihly, M., Watfa, A., Baranowski, B. J., Nakagawa, H., Taigen, T. L., Varma, N., et al. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.06.036 · Cited by 17 · see citing works
Self-citationRecent-onset atrial fibrillation: challenges and opportunities
Svennberg, E., Freedman, B., Andrade, J. G., Anselmino, M., Biton, Y., Boriani, G., Brandes, A., Buckley, C. M., Cameron, A. C., Clua‐Espuny, J. L., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf478 · Cited by 19 · see citing works
Self-citationPredictors of Late Atrial Fibrillation Recurrence After Cardiac Surgery
William, J., Rowe, K., Hogarty, J., Xiao, X., Shirwaiker, A., Bloom, J. E., Marasco, S., Zimmet, A. D., Merry, C., Negri, J. C., et al. (2024) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.05.030 · Cited by 19 · see citing works
Atrial Fibrillation in the Young
D’Elia, N. W., Kistler, P. M., & Voskoboinik, A. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.04.001 · Cited by 18 · see citing works
Left Atrial Appendage Occlusion and Post-procedural Antithrombotic Management
Kramer, A. D., Patti, G., Nielsen‐Kudsk, J. E., Berti, S. L., & Korsholm, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030803 · Cited by 16 · see citing works
May, J. E., & Moll, S. (2024) · Blood · doi:10.1182/blood.2023021638 · Cited by 17 · see citing works
Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction
Zeitler, E. P., Johnson, A. E., Cooper, L. B., Steinberg, B. A., & Houston, B. A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.06.016 · Cited by 16 · see citing works
Self-citationFüting, A., Neven, K. G. E. J., Bordignon, S., Reichlin, T., Blaauw, Y., Hansen, J., Adeliño, R., Ouss, A. J., Roten, L., Mulder, B. A., et al. (2024) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.124.013088 · Cited by 16 · see citing works
Cheung, J., Cheung, B. M. Y., Yiu, K., Tse, H., & Chan, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1573841 · Cited by 15 · see citing works
Guo, J., Song, Z., Wang, S., Yao, D., Yu, H., Fu, M., Chen, M., Jiang, W., Zhang, Y., Wu, S., et al. (2025) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.125.014069 · Cited by 15 · see citing works
Li, M., Ren, L., He, L., Lai, Y., Wang, J., Li, S., Peng, X., Zhao, M., Li, Q., Zhao, Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.394 · Cited by 15 · see citing works
Outcomes of Atrial Fibrillation Ablation Among Older Adults in the United States
Ferro, E. G., Reynolds, M. R., Xu, J., Song, Y., Cohen, D. J., Wadhera, R. K., d’Ávila, A., ZIMETBAUM, P. J., Yeh, R. W., & Kramer, D. B. (2024) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.03.032 · Cited by 15 · see citing works
Aarnink, E. W., Maarse, M., Fierro, N., Mazzone, P., Beneduce, A., Tondo, C., Gasperetti, A., Pracoń, R., Demkow, M., Zieliński, K., et al. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2024.04.012 · Cited by 15 · see citing works
Telles, J. P. M., Cenci, G. I., Marinheiro, G., Nager, G. B., Rocha, R. B., Bomtempo, F. F., Figueiredo, E. G., & Silva, G. S. (2024) · International Journal of Stroke · doi:10.1177/17474930241270443 · Cited by 15 · see citing works
Shurrab, M., Austin, P. C., Jackevicius, C. A., Tu, K., Qiu, F., Haldenby, O., Davies, S., Lópes, R. D., Baykaner, T., Johnson, L., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.08.033 · Cited by 15 · see citing works
Salerno, N., Ielapi, J., Cersosimo, A., Leo, I., Sabatino, J., Rosa, S. D., Sorrentino, S., & Torella, D. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae066 · Cited by 15 · see citing works
Chen, Y., Huang, B., Calvert, P. A. R., Liu, Y., Gue, Y. X., Gupta, D., McDowell, G., Azariah, J. L., Namboodiri, N., Unni, G., et al. (2024) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2024.100507 · Cited by 15 · see citing works
Lin, A. L., Allen, K. D., Gutierrez, J. A., Piccini, J. P., & Loring, Z. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.036899 · Cited by 14 · see citing works
Self-citationRodriguez‐Riascos, J. F., Vemulapalli, H. S., Akın, İ., Areiza, L. A., Rocca, D. G. D., Eitel, I., Fink, T., Genovesi, S., Kefer, J., Zweiker, D., et al. (2025) · EP Europace · doi:10.1093/europace/euaf198 · Cited by 14 · see citing works
Barbosa, L., Oliveira, V. M. R., Rivera, A., Araújo¹, B. D. S. G., Cabral, D. C. B. I., Consoli, L., Defante, M. L. R., Queiroz, I., Tartuce, L. P., Nunes, M. C. P., et al. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2025.12.037 · Cited by 14 · see citing works
An Overview of Arrhythmias in Pregnancy
Tamirisa, K. P., Oliveros, E., Paulraj, S., Mares, A. C., & Volgman, A. S. (2024) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1325 · Cited by 14 · see citing works
Self-citationThromboembolic risk and oral anticoagulation in subclinical atrial fibrillation
Wegner, F. K., & Eckardt, L. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.04.001 · Cited by 14 · see citing works
Fibrinaloid Microclots and Atrial Fibrillation
Kell, D. B., Lip, G. Y. H., & Pretorius, E. (2024) · Biomedicines · doi:10.3390/biomedicines12040891 · Cited by 13 · see citing works
Gilbers, M. D., Kawczynski, M. J., Bidar, E., Maesen, B. A. E., Isaacs, A. J., Winters, J., Linz, D., Rienstra, M., Gelder, I. C. V., Maessen, J. G., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.08.014 · Cited by 14 · see citing works
Potpara, T., Grygier, M., Hæusler, K. G., Nielsen‐Kudsk, J. E., Berti, S. L., Genovesi, S., Marijon, É., Bovéda, S., Tzikas, A., Boriani, G., et al. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2469-4896 · Cited by 14 · see citing works
Nakasone, K., Rocca, D. G. D., Magnocavallo, M., Betancur-Gutiérrez, A., Vetta, G., Pannone, L., Sorgente, A., Audiat, C., Rodríguez, J. Á.-C., Doundoulakis, I., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.01.025 · Cited by 13 · see citing works
Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation
Wallentin, L. C., Lindbäck, J., Hijazi, Z., Oldgren, J., Carnicelli, A., Alexander, J. H., Berg, D. D., Eikelboom, J. W., Goto, S., Lópes, R. D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.052 · Cited by 13 · see citing works
Pereyra, M., Farina, J., Scalia, I. G., Roarke, M. C., Mahmoud, A., Masson, R., Wasef, B., Tagle‐Cornell, C., Kenyon, C. R., Abbas, M. T., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.12.017 · Cited by 13 · see citing works
Sleep Disruption and Atrial Fibrillation: Evidence, Mechanisms and Clinical Implications
Deshmukh, A. J., Covassin, N., Dauvilliers, Y. A., & Somers, V. K. (2025) · Circulation Research · doi:10.1161/circresaha.125.325612 · Cited by 14 · see citing works
Outcomes and Management of Stressor-Associated Atrial Fibrillation
Haimovich, J. S., Kany, S., Ajufo, E. C., Andrade, J. G., Benjamin, E. J., Healey, J. S., Kirchhof, P. F., Lubitz, S. A., McIntyre, W. F., Rienstra, M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.031 · Cited by 13 · see citing works
Self-citationSegan, L. A., Kistler, P. M., Chieng, D., Crowley, R. F., William, J., Cho, K. K., Sugumar, H., Ling, L., Voskoboinik, A., Hawson, J. J., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.09.059 · Cited by 13 · see citing works
Self-citationEmbryological Classification of Arrhythmogenic Triggers Initiating Atrial Fibrillation
Ikenouchi, T., Nitta, J., Inaba, O., Negishi, M., Amemiya, M., Kono, T., Yamamoto, T., Murata, K., Kawamura, I., Goto, K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.060 · Cited by 13 · see citing works
Lima, N. A., Filho, F. W. P. A., Mendes, B. X., Neto, V. L. M., & d’Ávila, A. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.11.035 · Cited by 13 · see citing works
Machine Learning Predicts Bleeding Risk in Atrial Fibrillation Patients on Direct Oral Anticoagulant
Chaudhary, R., Nourelahi, M., Thoma, F. W., Gellad, W. F., Lo‐Ciganic, W., Chaudhary, R., Dua, A., Bliden, K. P., Gurbel, P. A., Neal, M. D., et al. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.02.030 · Cited by 13 · see citing works
- Authors
- Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., Linta, K. T., Marcus, G. M., McCarthy, P. M., Patel, N., Patton, K. K., Perez, M. V., Piccini, J. P., Russo, A. M., Sanders, P., Streur, M. M., Thomas, K. L., Times, S., Tisdale, J. E., Valente, A. M., Van Wagoner, D. R., Krahn, A. D., Andrade, J. G., Beavers, C. J., Bischoff, J. M., Bunch, T. J., Campbell, K. B., Chen, L. Y., Dharia, R., Dorsch, M. P., Gerstenfeld, E. P., Jones, A. E., Kaluzna, S. D., Masha, L., Nault, I., Noseworthy, P. A., Pellegrini, C. N., Tzeis, S. E., Volgman, A. S., & Zeitler, E. P.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Cleveland Clinic Lerner College of Medicine (US)
- University of Health Sciences and Pharmacy (US)
- Boston University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Temple University Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Wisconsin–Madison (US)
- University of Louisville (US)
- Denver VA Medical Center (US)
- Stanford Medicine (US)
- Columbia University Irving Medical Center (US)
- University of Arizona (US)
- West Virginia University (US)
- Mayo Clinic (US)
- University of California, San Francisco (US)
- Northwestern Medicine (US)
- University of Washington (US)
- Stanford University (US)
- Duke University (US)
- Royal Adelaide Hospital (AU)
- American College of Cardiology (US)
- Indiana University School of Medicine (US)
- Brigham and Women's Hospital (US)
- ORCID
- Joglar, José A.
- Chung, Mina K.
- Armbruster, Anastasia L.
- Benjamin, Emelia J.
- Chyou, Janice Y.
- Cronin, Edmond M.
- Deswal, Anita
- Eckhardt, Lee L.
- Goldberger, Zachary D.
- Gopinathannair, Rakesh
- Hess, Paul L.
- Hlatky, Mark
- Ibeh, Chinwe
- Indik, Julia H.
- Kido, Kazuhiko
- Kusumoto, Fred
- Link, Mark S.
- Marcus, Gregory M.
- McCarthy, Patrick M.
- Patel, Nimesh
- Patton, Kristen K.
- Perez, Marco V.
- Piccini, Jonathan P.
- Russo, Andrea M.
- Sanders, Prashanthan
- Streur, Megan M.
- Thomas, Kevin L.
- Tisdale, James E.
- Valente, Anne Marie
- Krahn, Andrew D.
- Andrade, Jason G.
- Beavers, Craig J.
- Bunch, T. Jared
- Campbell, Kristen Bova
- Chen, Lin Yee
- Dharia, Robin
- Dorsch, Michael P.
- Jones, Aubrey E.
- Kaluzna, Stephanie Dwyer
- Masha, Luke
- Nault, Isabelle
- Noseworthy, Peter A.
- Pellegrini, Cara N.
- Tzeis, Stylianos E.
- Volgman, Annabelle Santos
- Zeitler, Emily P.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 83
- Issue
- 1
- Pages
- 109-279
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC11104284
- OpenAlex
- W4389165660
- Semantic Scholar
- 6b9e178eb1680000a7b88c27e8b90f736019ac3f
- Cited by
- 933
- References
- 1,396
- Citations by year
- 2026: 383 · 2025: 336 · 2024: 213 · 2023: 1
- FWCI
- 183.62
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc)
- Funders
- U.S. Department of Veterans Affairs (IK6 BX006185)
- National Heart, Lung, and Blood Institute (R01HL158071, P01HL158502)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Keywords
- atrial fibrillation, diagnosis, management, thromboembolic risk assessment, anticoagulation, left atrial appendage closure, catheter ablation, surgical ablation, risk factor control, atrial fibrillation prevention, cardiac arrhythmias
- MeSH terms
- American Heart Association, Atrial Fibrillation, Cardiology, Humans, Risk Factors, Thromboembolism, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
